Split (3)

train · 29.5k rows

FEATURE_phases list	FEATURE_enrollmentCount int64	FEATURE_allocation string	FEATURE_interventionModel string	FEATURE_primaryPurpose class label	FEATURE_masking class label	FEATURE_healthyVolunteers bool	FEATURE_sex class label	FEATURE_oversightHasDmc bool	FEATURE_briefSummary string	FEATURE_detailedDescription string	FEATURE_conditions string	FEATURE_conditionsKeywords string	FEATURE_protocolPdfText string	FEATURE_numArms int64	FEATURE_armDescriptions string	FEATURE_armGroupTypes list	FEATURE_numInterventions int64	FEATURE_interventionTypes list	FEATURE_interventionDescriptions string	FEATURE_interventionNames string	FEATURE_numLocations int64	FEATURE_locationDetails string	LABEL_ct_level_ade_population int64	METADATA_nctId string	METADATA_overallStatus class label	METADATA_completionDate date32	METADATA_startDate date32	METADATA_leadSponsorName string	METADATA_leadSponsorClass class label	METADATA_hasProtocol bool	METADATA_hasSap bool	METADATA_hasIcf bool	METADATA_protocolPdfLinks string	METADATA_wilson_lower_bound float32
[ 3 ]	10	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The investigators hypothesize that, in addition to its apoptotic effect, clofarabine induces DNA hypomethylation. If the investigators' hypothesis is correct, findings from the present proposal will not only contribute to information relating to the mechanisms of action of clofarabine but also provide the opportunity f...	Study Overview This study will recruit patients who have received at least six cycles of 5-azacytidine without response or whose disease has progressed or relapsed while on 5-azacytidine. The first cohort of patients will receive clofarabine 10 mg/m2/day for five days and the second cohort of patients 5 mg/m2/day for ...	Myelodysplastic Syndromes	Myelodysplastic Syndromes	null	2	arm 1: Patients were treated with Clofarabine 10 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progress...	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: 10 mg/m2 x 5 days per 4 to 6 week cycles intervention 2: 5 mg/m2 x 5 days per 4 to 6 week cycles	intervention 1: Clofarabine intervention 2: Clofarabine	1	Amarillo \| Texas \| United States \| -101.8313 \| 35.222	10	NCT00700011	6TERMINATED	2010-03-01	2008-03-01	Texas Oncology Cancer Center	4INDUSTRY	false	false	false	null	0
[ 5 ]	59	RANDOMIZED	PARALLEL	1PREVENTION	1SINGLE	false	0ALL	true	This study is to investigate the effect of Sodium Bicarbonate bolus injection in patients undergoing an emergent coronary procedure for prevention of contrast-induced nephropathy.	This study is to investigate the effect of Sodium Bicarbonate bolus injection in patients undergoing an emergent coronary procedure for prevention of contrast-induced nephropathy.The End point is development of contrast-induced nephropathy.	Emergent Coronary Procedure	Patients undergoing an emergent coronary procedure	null	2	arm 1: None arm 2: None	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: 8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure intervention 2: 8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours ...	intervention 1: Sodium bicarbonate intervention 2: Sodium Chloride	1	Osaka \| N/A \| Japan \| 135.50107 \| 34.69379	59	NCT00700375	1COMPLETED	2010-03-01	2008-07-01	Osaka General Medical Center	7OTHER	false	false	false	null	0
[ 5 ]	2	NA	SINGLE_GROUP	0TREATMENT	0NONE	true	1FEMALE	true	The purpose of this study is to determine whether 6 months of fiber supplementation will improve ovulation in women with polycystic ovary syndrome (PCOS).	We hypothesize that 6 months of fiber supplementation will improve ovulation in women with PCOS by improving insulin sensitivity independent of weight loss. In this pilot study, we will determine the feasibility of conducting a larger double-blind, randomized trial in women with PCOS to test this hypothesis. We will ev...	PCOS		null	1	arm 1: 2 tablespoons daily	[ 0 ]	1	[ 0 ]	intervention 1: Liquid fiber supplement, 2 tablespoons twice daily.	intervention 1: Fiber-Stat	1	Richmond \| Virginia \| United States \| -77.46026 \| 37.55376	2	NCT00703092	6TERMINATED	2010-03-01	2008-02-01	Virginia Commonwealth University	7OTHER	false	false	false	null	0
[ 0 ]	115	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	true	0ALL	true	The purpose of this study is to compare the incidence of nausea, vomiting, need for rescue medication, prolonged PACU time, and unplanned hospital admission in patients with high risk for post-operative nausea and vomiting (PONV) treated with oral aprepitant with or without transdermal scopolamine preoperatively.	Aprepitant, a selective antagonist of neurokinin-1 (NK-1) receptors, blocks the emetic effects of substance P. NK-1 receptors are found on vagal afferents in the gastrointestinal tract and in the nucleus tractus solitaries in the brain. Substance P action on the NK-1 receptors in the central nervous system (CNS) is one...	Nausea Vomiting	postoperative nausea and vomiting	null	2	arm 1: Patients receive aprepitant and scopolamine for prevention of postoperative nausea and vomiting then were followed through the post operative period looking for nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine placebo looking for a...	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia intervention 2: Scopolamine transdermal applied to skin behind the ear one hour prior to surgery	intervention 1: Aprepitant intervention 2: Scopolamine	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	115	NCT00717054	1COMPLETED	2010-03-01	2008-02-01	Drexel University	7OTHER	false	false	false	null	0
[ 0 ]	42	NON_RANDOMIZED	PARALLEL	7BASIC_SCIENCE	0NONE	true	0ALL	true	We propose to study and compare measures of brain energy metabolism in geriatric bipolar individuals and healthy older adults. We would also like to investigate changes in brain energy metabolites and in vivo creatine kinase (CK) enzymatic activity associated with CoQ10 administration in older bipolar individuals.	Hypotheses 1. At baseline, the forward rate constant (kfor) of CK enzymatic activity in the frontal lobe of older subjects with bipolar depression will be significantly decreased relative to that of age-matched healthy controls. 2. After 8 weeks of treatment, bipolar depression subjects will demonstrate an increase in...	Bipolar Depression	Bipolar depression elderly Coenzyme Q10 Magnetic resonance spectroscopy	null	2	arm 1: Open Label Study arm 2: Healthy controls completed all study procedures completed by the CoQ10 group but did not receive any study medication.	[ 0, 4 ]	1	[ 0 ]	intervention 1: CoEnzyme Q10 with dosage range from 400 mg to 1200 mg per day	intervention 1: CoEnzyme Q10	1	Belmont \| Massachusetts \| United States \| -71.17867 \| 42.39593	19	NCT00720369	1COMPLETED	2010-03-01	2008-07-01	Mclean Hospital	7OTHER	false	false	false	null	0
[ 3 ]	35	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to further assess the potency of PF-00868554, an HCV polymerase inhibitor, in subjects chronically infected with HCV by evaluating the antiviral activity of PF-00868554 in combination with current standard of care therapy, pegylated interferon-alpha2a (PEGASYS) and ribavirin (COPEGUS).	null	Hepatitis C		null	4	arm 1: 500 mg BID arm 2: 300 mg BID arm 3: 200 mg BID arm 4: Placebo	[ 0, 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks. intervention 2: 300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional ...	intervention 1: PF-00868554 intervention 2: PF-00868554 intervention 3: PF-00868554 intervention 4: Placebo	10	La Jolla \| California \| United States \| -117.2742 \| 32.84727 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Orlando \| Florida \| United States \| -81.37924 \| 28.53834 Springfield \| Massachusetts \| United States \| -72.58981 \| 42.10148 New York \| New York \| United States \| -74.00597 \| 40.71427 New York ...	35	NCT00720434	1COMPLETED	2010-03-01	2008-08-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 4 ]	158	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to evaluate the safety and efficacy of ustekinumab (CNTO 1275) compared with placebo in participants with moderate to severe plaque type psoriasis.	This is a multicenter (involving more than 1 study center), randomized (study medication assigned by chance), double-blind (neither the invesitigator nor the participant knows the identity of the study medication), placebo- controlled (1 of the study medications is inactive), parallel-group comparative study (different...	Psoriasis	Psoriasis Ustekinumab CNTO 1275	null	7	arm 1: Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12). arm 2: Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12). arm 3: Ustekinumab 90 mg (1.0 ml) and ...	[ 2, 1, 1, 2, 2, 1, 1 ]	7	[ 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12). intervention 2: Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12). intervention 3: Uste...	intervention 1: Placebo (CP) intervention 2: Ustekinumab 45 mg (CP) intervention 3: Ustekinumab 90 mg (CP) intervention 4: Placebo A (After CP) intervention 5: Placebo B (After CP) intervention 6: Ustekinumab 45 mg (After CP) intervention 7: Ustekinumab 90 mg (After CP)	27	Asahikawa \| N/A \| Japan \| 142.36489 \| 43.77063 Chitose \| N/A \| Japan \| 141.65222 \| 42.81944 Chūō \| N/A \| Japan \| 139.77544 \| 35.67004 Fukuoka \| N/A \| Japan \| 130.41667 \| 33.6 Fushimi \| N/A \| Japan \| 138.89742 \| 35.11426 Isehara \| N/A \| Japan \| 139.31019 \| 35.39932 Kanazawa \| N/A \| Japan \| 136.61667 \| 36.6 Kurume \| N/A ...	312	NCT00723528	1COMPLETED	2010-03-01	2008-03-01	Janssen Pharmaceutical K.K.	4INDUSTRY	false	false	false	null	0
[ 3 ]	28	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Paclitaxel is known to be active as a single and combination agent in esophageal cancer, and has also been demonstrated to have anti-angiogenic properties in weekly dosing regimens. Sunitinib malate is an anti-angiogenic drug with the potential to improve responses when combined with chemotherapy, as demonstrated with ...	OUTLINE: This is a multi-center study. Treatment will be administered on an outpatient basis. Chemotherapy will be administered in a 28-day treatment cycle. The 28 days of treatment with paclitaxel and sunitinib malate (plus the time required to recover if toxicity is encountered) is defined as a cycle. * Paclitaxel ...	Esophageal Cancer		null	1	arm 1: Treatment will be administered on an outpatient basis. Chemotherapy will be administered in a 28-day treatment cycle. The 28 days of treatment with paclitaxel and sunitinib malate (plus the time required to recover if toxicity is encountered) is defined as a cycle. * Paclitaxel 90 mg/m2 IV on days 1, 8 and 15. ...	[ 0 ]	2	[ 0, 0 ]	intervention 1: Sunitinib malate 37.5 mg orally, daily intervention 2: Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.	intervention 1: Sunitinib malate intervention 2: Paclitaxel	15	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Galesburg \| Illinois \| United States \| -90.37124 \| 40.94782 Bloomington \| Indiana \| United States \| -86.52639 \| 39.16533 Evansville \| Indiana \| United States \| -87.55585 \| 37.97476 Fort Wayne \| Indiana \| ...	28	NCT00730353	1COMPLETED	2010-03-01	2008-08-01	Hoosier Cancer Research Network	7OTHER	false	false	false	null	0
[ 4 ]	121	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The purpose of this study is to evaluate the efficacy and safety of Ustekinumab in the treatment of patients with moderate to severe psoriasis in South Korea and Taiwan.	This is phase 3, multicenter, randomized, placebo-controlled double-blind, parallel study of subcutaneous injection of placebo and ustekinumab 45mg in Taiwanese and Korean patients with moderate to severe plaque psoriasis. Ustekinumab is an experimental medicine that is being tested to see if it may be useful in treati...	Psoriasis	Psoriasis Psoriatic Arthritis Ustekinumab CNTO 1275	null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 2, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Placebo, Weeks 0-12 intervention 2: Ustekinumab 45 mg, Weeks 0-12 intervention 3: Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16 intervention 4: Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16	intervention 1: Placebo - Controlled Period (CP) intervention 2: Ustekinumab 45 mg - CP intervention 3: Placebo to ustekinumab 45 mg - after CP intervention 4: Ustekinumab 45 mg - after CP	5	Anyang \| N/A \| South Korea \| 127.1464 \| 36.9577 Seoul \| N/A \| South Korea \| 126.9784 \| 37.566 Changhua \| N/A \| Taiwan \| 120.5512 \| 24.0692 Kaohsiung County \| N/A \| Taiwan \| N/A \| N/A Taipei \| N/A \| Taiwan \| 121.52639 \| 25.05306	235	NCT00747344	1COMPLETED	2010-03-01	2008-12-01	Centocor, Inc.	4INDUSTRY	false	false	false	null	0
[ 2 ]	112	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This study will asses the safety, tolerability, multiple-dose pharmacokinetics and pharmacodynamics of MK1006 in participants with type 2 diabetes.	null	Type 2 Diabetes		null	10	arm 1: After a 2-week run-in/wash-off period, participants received single daily doses (q.d.) of 20 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the Clinical Research Unit (CRU). arm 2: After a 2-week run-in/wash-off period, participants received single daily doses of 40 mg MK-1006 over ...	[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period. intervention 2: Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.	intervention 1: MK-1006 intervention 2: Comparator: Placebo comparator	0	null	112	NCT00758680	6TERMINATED	2010-03-01	2008-08-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0
[ 4 ]	1,179	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to evaluate the safety and efficacy of Moxifloxacin AF Ophthalmic Solution compared to Moxifloxacin AF Vehicle in the treatment of bacterial conjunctivitis in patients one month of age or older.	null	Bacterial Conjunctivitis	pink eye conjunctivitis moxifloxacin fluoroquinolone	null	2	arm 1: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, 1 drop in each eye twice daily for 3 days arm 2: Moxifloxacin AF vehicle, 1 drop in each eye twice daily for 3 days	[ 0, 2 ]	2	[ 0, 10 ]	intervention 1: Eye drops intervention 2: Inactive ingredients used as a placebo for masking purposes	intervention 1: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5% intervention 2: Moxifloxacin AF Vehicle	0	null	1,179	NCT00759148	1COMPLETED	2010-03-01	2008-10-01	Alcon Research	4INDUSTRY	false	false	false	null	0
[ 2 ]	29	NON_RANDOMIZED	CROSSOVER	null	0NONE	true	0ALL	false	This study will evaluate what effect renal dysfunction has on a drug that has an intravenous (CP-70,429) and an oral form (PF-03709270).	To evaluate the pharmacokinetics and safety.	Pneumonia		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).	intervention 1: CP-70,429 and PF-03709270	2	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838 Brussels \| N/A \| Belgium \| 4.34878 \| 50.85045	57	NCT00759564	1COMPLETED	2010-03-01	2008-11-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 3 ]	32	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This is a phase II, open-label, multicenter, dual-strata study designed to evaluate the efficacy and safety of IV romidepsin given in combination with IV bortezomib for multiple myeloma (MM) patients with refractory or relapsed disease. Patients will be enrolled into one of two strata, bortezomib-resistant or bortezomi...	null	Multiple Myeloma	Multiple Myelonoma Romidepsin Bortezomib	null	1	arm 1: Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period. Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.	[ 0 ]	2	[ 0, 0 ]	intervention 1: Bortezomib was administered at a dose of 1.0 mg/m\^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin inf...	intervention 1: Bortezomib intervention 2: Romidepsin	12	Loma Linda \| California \| United States \| -117.26115 \| 34.04835 Rancho Mirage \| California \| United States \| -116.41279 \| 33.73974 Santa Barbara \| California \| United States \| -119.69819 \| 34.42083 West Hollywood \| California \| United States \| -118.36174 \| 34.09001 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749...	32	NCT00765102	6TERMINATED	2010-03-01	2008-09-01	Celgene	4INDUSTRY	false	false	false	null	0
[ 3, 4 ]	337	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The purpose of this study is to evaluate the efficacy and safety of E3810 tablets in patients with Proton Pump Inhibitor-resistant reflux esophagitis.	This is a multicenter, randomized, double-blinded study. The efficacy with E3810 20 mg once daily is compared with E3810 20 mg twice daily and 10 mg twice daily using endoscopic recovery. The frequency of adverse event, etc., will be compared among 3 groups for safety assessment.	Refractory Reflux Esophagitis	reflux esophagitis rabeprazole GERD Japan	null	3	arm 1: None arm 2: None arm 3: None	[ 1, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: 20 mg taken orally, once a day for 8 weeks. intervention 2: 10 mg, taken orally, twice a day for 8 weeks. intervention 3: 20 mg taken orally, twice a day for 8 weeks.	intervention 1: E3810 intervention 2: E3810 intervention 3: E3810	54	Nagakute \| Aichi-ken \| Japan \| 137.05667 \| 35.17325 Nagoya \| Aichi-ken \| Japan \| 136.90641 \| 35.18147 Akita \| Akita \| Japan \| 140.11667 \| 39.71667 Abiko \| Chiba \| Japan \| 140.01667 \| 35.86667 Kashiwa \| Chiba \| Japan \| 139.97732 \| 35.86224 Yachiyo \| Chiba \| Japan \| 140.12445 \| 35.73531 Chikushino-shi \| Fukuoka \| Japan \|...	337	NCT00770913	1COMPLETED	2010-03-01	2008-10-01	Eisai Co., Ltd.	4INDUSTRY	false	false	false	null	0
[ 4 ]	140	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This single arm study will assess the long term maintenance of hemoglobin (Hb) levels, safety and tolerability of once monthly subcutaneous methoxy polyethylene glycol-epoetin beta (CERA) in predialysis participants with chronic renal anemia. Participants currently receiving subcutaneous darbopoetin alfa maintenance tr...	null	Anemia		null	1	arm 1: Participants will receive methoxy polyethylene glycol-epoetin beta once monthly by subcutaneous (SC) injection for 28 weeks.	[ 0 ]	1	[ 0 ]	intervention 1: 120, 200 or 360 micrograms every 4 weeks by subcutaneous injection.	intervention 1: Methoxy Polyethylene Glycol-Epoetin Beta	34	Barletta \| Apulia \| Italy \| 16.28165 \| 41.31429 Molfetta (Ba) \| Apulia \| Italy \| 16.59905 \| 41.20036 Putignano \| Apulia \| Italy \| 17.1219 \| 40.85106 Caserta \| Campania \| Italy \| 14.33231 \| 41.07262 Eboli \| Campania \| Italy \| 15.05693 \| 40.61747 Napoli \| Campania \| Italy \| 14.5195 \| 40.87618 Nola \| Campania \| Italy \| 14...	111	NCT00773968	1COMPLETED	2010-03-01	2008-09-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0
[ 5 ]	27	RANDOMIZED	SINGLE_GROUP	0TREATMENT	1SINGLE	false	0ALL	false	The purpose of this study is to determine if use of topical imiquimod cream after cryotherapy of actinic keratoses reduces the total number of lesions (those treated with cryotherapy and new ones) at follow-up.	Actinic keratoses are common skin lesions associated with excess sun exposure. Over time, there is a small risk a lesion may progress to skin cancer. Since one can not predict which actinic keratosis will progress, the standard of care is to treat the lesions. The most commonly used method to treat actinic keratoses in...	Actinic Keratoses	Combination treatment Imiquimod Cryotherapy	null	2	arm 1: Imiquimod 5% cream, 1 packet (250 mg cream), applied to left or right treatment area on the face and/or balding scalp arm 2: No treatment of treatment area on the other half of the face and/or balding scalp	[ 0, 4 ]	1	[ 0 ]	intervention 1: 1 packet (250 mg cream) 3 times per week for 4 weeks	intervention 1: imiquimod 5% cream	3	St. Petersburg \| Florida \| United States \| -82.67927 \| 27.77086 Henderson \| Nevada \| United States \| -114.98194 \| 36.0397 New York \| New York \| United States \| -74.00597 \| 40.71427	27	NCT00774787	1COMPLETED	2010-03-01	2008-10-01	Rigel Dermatology	7OTHER	false	false	false	null	0
[ 3 ]	4	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	false	The purpose of the study is to assess the benefit of panobinostat monotherapy given either orally or i.v. to women with HER2-positive locally recurrent or metastatic breast cancer	null	Breast Cancer		null	2	arm 1: None arm 2: None	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Solution for infusion - 25mg/5ml intervention 2: Hard gelatine capsules - 5mg and 20 mg	intervention 1: Panobinostat - LBH589 intervention 2: Panobinostat - LBH589	1	Los Angeles \| California \| United States \| -118.24368 \| 34.05223	4	NCT00777335	6TERMINATED	2010-03-01	2009-02-01	Translational Research in Oncology	7OTHER	false	false	false	null	0
[ 0 ]	72	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	Little is known about the support needed to improve compliance with Chantix for smoking cessation. This is a two arm pilot study of African American smokers to provide varying levels of side effect management and compliance support during a 12 week treatment period. The primary aim of the study is to estimate the effec...	null	Smokers	African american smokers smoking cessation African American smokers	null	2	arm 1: Chantix for 3 months and Standard Counseling arm 2: Chantix for 3 months and Adherence Counseling	[ 1, 0 ]	3	[ 0, 5, 5 ]	intervention 1: Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3 intervention 2: Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of ...	intervention 1: Chantix intervention 2: Adherence Counseling intervention 3: Standard Counseling	1	Kansas City \| Kansas \| United States \| -94.62746 \| 39.11417	72	NCT00781599	1COMPLETED	2010-03-01	2008-10-01	Nikki Nollen, PhD, MA	7OTHER	false	false	false	null	0
[ 3 ]	48	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to evalute the response and toxicity of metastatic colorectal cancer patients to the regimen of gamma interferon added to bolus and infusional 5-fluorouracil and leucovorin (GFL) with or without bevacizumab.	null	Colorectal Cancer	Gamma Interferon 5-FU LV	null	2	arm 1: Patients in stratum 1 have not received prior chemotherapy in the metastatic setting. arm 2: Patients in stratum 2 have received 1-2 prior chemotherapy regimens in the metastatic setting.	[ 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 5-FU bolus was administered at 400mg/m\^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m\^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle. intervention 2: Leucovorin 200mg/m\^2 was administered over 2 hours on day 1 and day 2 of each cycle. intervention 3: Gamma-Interferon...	intervention 1: 5-Fluorouracil intervention 2: Leucovorin (LV) intervention 3: Gamma-Interferon-1b (IFN-γ) intervention 4: Bevacizumab	1	Memphis \| Tennessee \| United States \| -90.04898 \| 35.14953	47	NCT00786643	1COMPLETED	2010-03-01	2006-02-01	Accelerated Community Oncology Research Network	7OTHER	false	false	false	null	0
[ 4 ]	101	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	true	0ALL	false	Varenicline (Champix) is a relatively new medicine that is effective in helping people to quit smoking. It is normally started 1-week before stopping smoking and used for up to 12-24 weeks. We are trying to find out if using varenicline for an extended time (4-weeks) before stopping smoking is better than the standard ...	null	Tobacco Dependence Smoking Cessation	Smoking cessation Tobacco dependence Varenicline Preloading	null	2	arm 1: Participants will use varenicline (1mg BD) 4-weeks prior to quitting arm 2: Participants will use 3 weeks of placebo, followed by 1 week of varenicline, prior to quitting	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Varenicline 1mg twice daily intervention 2: Placebo 1mg BD	intervention 1: Varenicline intervention 2: Placebo	1	London \| N/A \| United Kingdom \| -0.12574 \| 51.50853	101	NCT00789074	1COMPLETED	2010-03-01	2009-07-01	Queen Mary University of London	7OTHER	false	false	false	null	0
[ 3 ]	11	RANDOMIZED	CROSSOVER	4SUPPORTIVE_CARE	3TRIPLE	false	0ALL	true	The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a treatment for cancer-related fatigue. The central hypothesis of this pilot study is that TRH is more efficacious than placebo in alleviating cancer-related fatigue in patients with breast or prostate cancer.	null	Cancer-related Fatigue	cancer fatigue	null	2	arm 1: TRH arm 2: Placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 0.5mg and 1.5mg intervention 2: Saline	intervention 1: Thyrotropin releasing hormone (TRH) intervention 2: Placebo	1	Farmington \| Connecticut \| United States \| -72.83204 \| 41.71982	16	NCT00790296	6TERMINATED	2010-03-01	2006-12-01	UConn Health	7OTHER	false	false	false	null	0
[ 3 ]	109	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease. Since there is no placebo in this study, all patients will be taking lithium carbonate.	This is a Phase II Screening study. There is no placebo (inactive or 'fake' drug) in this study, meaning that all participants will be taking lithium carbonate. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease. A recen...	Amyotrophic Lateral Sclerosis	ALS Amyotrophic Lateral Sclerosis Lou Gehrig's Disease Lithium Lithium Carbonate	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.	intervention 1: lithium carbonate	10	Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Orange \| California \| United States \| -117.85311 \| 33.78779 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Kansas City \| Kansas \| United States \| -94.62746 \| 39.11417 St Loui...	358	NCT00790582	1COMPLETED	2010-03-01	2008-05-01	Forbes Norris MDA/ALS Research Center	7OTHER	false	false	false	null	0
[ 3 ]	63	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Objectives: Primary objective: Evaluate toxicity of rapamycin when used for post-bone marrow transplant graft vs. host disease prophylaxis in children with acute lymphoblastic leukemia (ALL). Investigator initiated; four participating institutions; Phase II pilot study	Objectives: Primary objective: Evaluate toxicity of rapamycin when used for post-bone marrow transplant graft vs. host disease prophylaxis in children with acute lymphoblastic leukemia (ALL). Rapamycin Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a ...	Acute Lymphoblastic Leukemia	ALL Cancer Stem Cell Transplant	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action...	intervention 1: RAPAMYCIN	1	Salt Lake City \| Utah \| United States \| -111.89105 \| 40.76078	63	NCT00795886	1COMPLETED	2010-03-01	2005-08-01	University of Utah	7OTHER	false	false	false	null	0
[ 3 ]	1	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to evaluate if the combination of oral budesonide and rectal hydrocortisone improves symptoms in patients with active ulcerative colitis. Also, we would like to determine if oral budesonide and rectal hydrocortisone has fewer and less severe side effects compared to standard steroids (predn...	Ulcerative colitis (UC) is a common chronic inflammatory condition of the intestines that results in bloody diarrhea, abdominal pain, and extraintestinal manifestations of disease. The disease course is typically chronic, characterized by periodic exacerbations followed by symptom- free intervals; less commonly symptom...	Inflammatory Bowel Disease Ulcerative Colitis	Inflammatory Bowel Disease Ulcerative Colitis Budesonide Corticosteroids	null	1	arm 1: See intervention	[ 0 ]	1	[ 0 ]	intervention 1: Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortis...	intervention 1: Combination Oral Budesonide and Rectal Hydrocortisone	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	1	NCT00805285	6TERMINATED	2010-03-01	2008-10-01	University of Maryland, Baltimore	7OTHER	false	false	false	null	0
[ 4 ]	102	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Azithromycin has high rates of clinical response and eradication, wide spectrum of activity, so we suppose the development of the azithromycin injectable formulation in Japan would deliver benefit to patients of community acquired pneumonia.	null	Community Acquired Pneumonia (CAP)		null	1	arm 1: Azithromycin switch therapy (switch from intravenous to oral)	[ 0 ]	1	[ 0 ]	intervention 1: The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.	intervention 1: Azithromycin	34	Seto-shi \| Aichi-ken \| Japan \| N/A \| N/A Touon \| Ehime \| Japan \| N/A \| N/A Chikushino-shi \| Fukuoka \| Japan \| 130.5156 \| 33.49631 Fukuoka \| Fukuoka \| Japan \| 130.41667 \| 33.6 Koga \| Fukuoka \| Japan \| 130.46667 \| 33.73333 Yanagawa \| Fukuoka \| Japan \| 130.4 \| 33.16667 Higashihiroshima \| Hiroshima \| Japan \| 132.73682 \| 34...	102	NCT00809328	1COMPLETED	2010-03-01	2009-02-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 5 ]	840	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This study investigates two different approaches to the change in antidepressant treatment when an initial treatment is not effective: early intervention or delayed intervention. Two hypothesis will be tested: 1. that time to confirmed response is shorter in the early intervention strategy vs. delayed intervention st...	null	Major Depressive Disorder	Major Depressive Disorder MDD Depression	null	2	arm 1: Escitalopram 10 milligrams per day for 4 weeks (one 10 milligram \[mg\]-capsule) followed by Duloxetine flexible dose (60 or 120 mg daily) for 12 weeks. arm 2: Escitalopram 10 mg per day for 4 weeks (one 10 mg-capsule) followed by Escitalopram 10 to 20 mg per day for 4 weeks (one or two 10 mg capsule\[s\]). Then...	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Flexible dose of 60 or 120 mg daily intervention 2: 10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.	intervention 1: Duloxetine Hydrochloride intervention 2: Escitalopram	60	Copenhagen \| N/A \| Denmark \| 12.56553 \| 55.67594 Angoulême \| N/A \| France \| 0.15345 \| 45.64997 Arcachon \| N/A \| France \| -1.17255 \| 44.66126 Dole \| N/A \| France \| 5.48966 \| 47.09225 Gujan-Mestras \| N/A \| France \| -1.06815 \| 44.636 Marseille \| N/A \| France \| 5.38107 \| 43.29695 Montpellier \| N/A \| France \| 3.87635 \| 43.6...	1,654	NCT00810069	1COMPLETED	2010-03-01	2008-11-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0
[ 4 ]	63	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this multicenter, open label study, is to evaluate the safety and efficacy of a 12-week treatment with Posaconazole Oral Suspension in participants with IFI	null	Fungal Infection	refractory or first line medication intolerable invasive fungal infection	null	1	arm 1: Posaconazole 400 mg twice a day (BID) oral suspension for 12 weeks	[ 0 ]	1	[ 0 ]	intervention 1: 400mg BID oral suspension for 12 weeks	intervention 1: Posaconazole	0	null	62	NCT00811642	1COMPLETED	2010-03-01	2008-11-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0
[ 4 ]	382	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to evaluate how tapentadol immediate release (IR) and oxycodone IR treat moderate to severe post-operative pain after elective arthroscopic shoulder surgery.	This is a double-blind (neither the patient nor the study doctor knows the name of the assigned study drug during the study), randomized (study drug selected by chance like flipping a coin), active-comparator (patient will get active drug and there is no inactive drug), outpatient study to evaluate efficacy and how wel...	Postoperative Pain	analgesia postoperative pain opioid rotator cuff repair labral tear repair Bankart procedure oxycodone tapentadol arthroscopic shoulder surgery	null	2	arm 1: Tapentadol IR First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1 if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed arm 2: Oxycodone IR First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon a...	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed intervention 2: First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one ho...	intervention 1: Tapentadol IR intervention 2: Oxycodone IR	0	null	378	NCT00814580	1COMPLETED	2010-03-01	2008-12-01	Ortho-McNeil Janssen Scientific Affairs, LLC	4INDUSTRY	false	false	false	null	0
[ 5 ]	1	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to determine whether the biologic medication alefacept (Amevive) is effective and safe in the treatment of Pityriasis Rubra Pilaris.	Pityriasis Rubra Pilaris (PRP) is a therapeutic challenge, and many different medication regimens exist to treat the condition. Clinical response is variable, and no single treatment has emerged as a leading therapy. Biologic agents have emerged as effective treatments for many skin diseases, including psoriasis. Given...	Pityriasis Rubra Pilaris	PRP Pityriasis Rubra Pilaris Amevive Alefacept Biologic Immunosuppressant Severe skin disease	null	1	arm 1: Treatment Group (only one group)	[ 0 ]	1	[ 0 ]	intervention 1: 15mg intramuscular injection weekly for 12 weeks	intervention 1: Alefacept	1	New York \| New York \| United States \| -74.00597 \| 40.71427	0	NCT00815633	6TERMINATED	2010-03-01	2008-12-01	Joshua Zeichner	7OTHER	false	false	false	null	0
[ 5 ]	97	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol, triglyceride) in patients with metabolic syndrome.	null	Metabolic Syndrome	plasma lipid profile metabolic syndrome	null	1	arm 1: medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.	[ 0 ]	1	[ 0 ]	intervention 1: medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.	intervention 1: rosuvastatin	6	Ankara \| Besevler \| Turkey (Türkiye) \| 32.85427 \| 39.91987 Kayseri \| Erciyes \| Turkey (Türkiye) \| 35.48528 \| 38.73222 Istanbul \| Haseki \| Turkey (Türkiye) \| 28.94966 \| 41.01384 Kocaeli \| Umuttepe \| Turkey (Türkiye) \| 27.51145 \| 39.62497 Izmir \| N/A \| Turkey (Türkiye) \| 27.13838 \| 38.41273 Trabzon \| N/A \| Turkey (Türkiy...	97	NCT00815659	1COMPLETED	2010-03-01	2008-12-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 5 ]	146	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This study will test the usefulness of the medication metformin in treating people with schizophrenia or schizoaffective disorder who are overweight and also taking antipsychotic medications.	Schizophrenia is a chronic mental disorder that is characterized, in part, by psychotic symptoms. Psychotic symptoms include hallucinations and delusions, in which a person has abnormal experiences or beliefs, and are commonly treated with antipsychotic medications. Unfortunately, a side effect of many antipsychotics i...	Schizophrenia	Schizoaffective Disorder	null	2	arm 1: Encapsulated metformin 1000-2000 mg/day arm 2: Matching placebo capsules 2-4 daily	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 500 mg to 1,000 mg taken twice daily for 16 weeks intervention 2: 1 to 2 placebo capsules taken twice daily for 16 weeks	intervention 1: Metformin intervention 2: Placebo	16	Palo Alto \| California \| United States \| -122.14302 \| 37.44188 Boca Raton \| Florida \| United States \| -80.0831 \| 26.35869 Iowa City \| Iowa \| United States \| -91.53017 \| 41.66113 Wichita \| Kansas \| United States \| -97.33754 \| 37.69224 Glen Burnie \| Maryland \| United States \| -76.62469 \| 39.16261 Boston \| Massachusetts \|...	146	NCT00816907	1COMPLETED	2010-03-01	2009-01-01	National Institute of Mental Health (NIMH)	0NIH	false	false	false	null	0
[ 3 ]	328	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat inhaler once daily for 4 weeks in Japanese patients with chronic obstructive pulmonary disease (COPD). The selection of the optimum dose(s) will be based on bronchodilator efficacy, safety...	null	Pulmonary Disease, Chronic Obstructive		null	4	arm 1: 2 puffs of 2.5 Âµg/actuation arm 2: 2 puffs of 5 Âµg/actuation arm 3: 2 puffs arm 4: 2 puffs of 1 Âµg/actuation	[ 0, 0, 2, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler intervention 2: 2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler intervention 3: 2 puffs of 5 Âµg/actuation delivered by RespimatÂ® intervention 4: 2 puffs delivered by the RespimatÂ® inhaler	intervention 1: BI 1744 CL 2 Âµg intervention 2: BI 1744 CL 5 Âµg intervention 3: BI 1744 CL 10 Âµg intervention 4: Placebo	48	Asahikawa, Hokkaido \| N/A \| Japan \| 142.36489 \| 43.77063 Bunkyo-ku, Tokyo \| N/A \| Japan \| N/A \| N/A Chiba, Chiba \| N/A \| Japan \| N/A \| N/A Fukuoka, Fukuoka \| N/A \| Japan \| N/A \| N/A Fukuoka, Fukuoka \| N/A \| Japan \| N/A \| N/A Himeji, Hyogo \| N/A \| Japan \| N/A \| N/A Himeji, Hyogo \| N/A \| Japan \| N/A \| N/A Hiroshima, Hiro...	328	NCT00824382	1COMPLETED	2010-03-01	2009-01-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0
[ 3 ]	154	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.	null	Chronic Kidney Disease	Hemodialysis	null	6	arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None	[ 0, 0, 0, 0, 0, 0 ]	6	[ 0, 0, 0, 0, 0, 0 ]	intervention 1: Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day. intervention 2: Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken ora...	intervention 1: 1.25 g PA21 (250 mg iron) intervention 2: 5.0 g PA21 (1,000 mg iron) intervention 3: 7.5 g PA21 (1,500 mg iron) intervention 4: 10.0 g PA21 (2,000 mg iron) intervention 5: 12.5 g PA21 (2,500 mg iron) intervention 6: Sevelamer hydrochloride	60	Arvada \| Colorado \| United States \| -105.08748 \| 39.80276 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Pembroke Pines \| Florida \| United States \| -80.22394 \| 26.00315 Kansas City \| Kansas \| United States \| -94.62746 \| 39.11417 Fresh Meadows \| New York \| United States \| -73.79347 \| 40.73482 Cleveland \| Ohio ...	154	NCT00824460	1COMPLETED	2010-03-01	2008-12-01	Vifor Pharma	4INDUSTRY	false	false	false	null	-0
[ 3 ]	34	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this research study was to evaluate ARX-F02 (Sufentanil NanoTab) versus placebo ("sugar" pill or inactive substance) in the management of breakthrough pain in cancer patients.	null	Cancer Pain	Cancer breakthrough pain	null	1	arm 1: During the Titration Phase, patients titrated to the effective dosage of sublingual sufentanil NanoTab™(20, 30, 40, 60 or 80 mcg). One sublingual sufentanil NanoTab™ was taken as needed for breakthrough pain. During the Double-Blind Phase, patients were then randomized to one of six treatment sequences, each of...	[ 0 ]	1	[ 0 ]	intervention 1: During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage dete...	intervention 1: Sublingual sufentanil NanoTabs™ and placebo NanoTabs™	13	Montebello \| California \| United States \| -118.10535 \| 34.00946 Jacksonville \| Florida \| United States \| -81.65565 \| 30.33218 Lakeland \| Florida \| United States \| -81.9498 \| 28.03947 Sarasota \| Florida \| United States \| -82.53065 \| 27.33643 Venice \| Florida \| United States \| -82.45426 \| 27.09978 Marietta \| Georgia \| Un...	34	NCT00833040	1COMPLETED	2010-03-01	2009-04-01	Talphera, Inc	4INDUSTRY	false	false	false	null	0
[ 3 ]	2	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to find out if a program of intensive chemotherapy with gemcitabine, docetaxel and capecitabine followed by an advanced form of focused radiation aimed at the patient's tumor followed by more chemotherapy can increase the chances that the patient's pancreatic tumor can be removed completely...	* Cycle 1 and 2: * Days 4, 11 and 25, 32 ....gemcitabine 750 mg/m\^2 intravenous piggy back (IVPB) over 30 min * Days 4, 11 and 25, 32 ....docetaxel 30 mg/m\^2 IVPB over 1 hour * Days 1-14 and 22-35 ....capecitabine 750 mg/m\^2 oral twice daily * Each cycle is 21 days long * SRS: Day 43 ....25 Gy single fracti...	Pancreatic Neoplasms	stereotactic radiosurgery borderline resectable pancreatic cancer gastrointestinal pancreas	null	1	arm 1: GTX-SRS: Gemcitabine, Taxotere, Xeloda (GTX)-Stereotactic Radiosurgery (SRS)	[ 0 ]	2	[ 0, 4 ]	intervention 1: GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14 intervention 2: stereotactic body radiation therapy (SBRT) 25	intervention 1: GTX (gemcitabine, docetaxel and capecitabine) intervention 2: stereotactic body radiation therapy	1	Tampa \| Florida \| United States \| -82.45843 \| 27.94752	2	NCT00833859	6TERMINATED	2010-03-01	2009-03-01	H. Lee Moffitt Cancer Center and Research Institute	7OTHER	false	false	false	null	0
[ 0 ]	17	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The purpose of this grant is to collect pilot data to assess the amount of botulinum toxin that needs to be injected into the calf muscles of subjects with diabetes mellitus, peripheral neuropathy, and a plantar ulcer to decrease muscle strength. We hypothesize that a decrease in plantar flexor muscle strength will tem...	Please read "Brief Summary"	Diabetes Mellitus Peripheral Neuropathy Plantar Ulcers	Diabetes mellitus plantar ulcers peripheral neuropathy	null	3	arm 1: Placebo (saline) injections into 6 sites in the calf muscle arm 2: Total 200 units of Botulinum Toxin injected into 6 sites into the calf muscles. arm 3: 300 units of botulinum toxin injected into 6 sites in the calf muscle	[ 2, 1, 1 ]	2	[ 0, 0 ]	intervention 1: 200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus intervention 2: Placebo (saline) (3cc). Injection are given at one session. 2 inje...	intervention 1: Botulinum Toxin intervention 2: Saline	1	St Louis \| Missouri \| United States \| -90.19789 \| 38.62727	17	NCT00845897	1COMPLETED	2010-03-01	2005-03-01	Washington University School of Medicine	7OTHER	false	false	false	null	0
[ 4 ]	1,134	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	This study assessed the efficacy and safety of indacaterol (150 µg once daily \[od\]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD)	null	Chronic Obstructive Pulmonary Disease (COPD)	chronic obstructive pulmonary disease COPD indacaterol tiotropium bronchodilation	null	2	arm 1: Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Dai...	[ 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device. intervention 2: Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®). intervention 3: Placebo to indacaterol was supplied ...	intervention 1: Indacaterol 150 μg intervention 2: Tiotropium 18 μg intervention 3: Placebo to indacaterol	137	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Pine Bluff \| Arkansas \| Unite...	1,131	NCT00846586	1COMPLETED	2010-03-01	2009-03-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 5 ]	249	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The purpose of this study is to evaluate in patients with Chronic Obstructive Pulmonary Disease (COPD) if Advair DISKUS™ 250/50mcg BID modifies arterial stiffness which is a measure associated with risk of heart disease.	This is a multicenter, randomized, double-blind, placebo controlled study to evaluate the effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg (FSC) BID on arterial stiffness in COPD subjects. Following a 1 to 14 day run-in period, approximately 250 subjects will be randomly assigned to double-blind treatment f...	Pulmonary Disease, Chronic Obstructive	Chronic Obstructive Pulmonary Disease arterial stiffness Computed Tomography pulse wave velocity Pulse wave analysis	null	2	arm 1: Subjects receive blinded Fluticasone Propionate/Salmeterol. At 4 months subjects will receive open label SPIRIVA HANDIHALER arm 2: Subjects will receive placebo ADVAIR DISKUS. At 4 months subjects will receive open label SPIRIVA HANDIHALER	[ 1, 2 ]	2	[ 0, 10 ]	intervention 1: ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with...	intervention 1: ADVAIR DISKUS™ 250/50mcg intervention 2: Placebo	24	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Jasper \| Alabama \| United States \| -87.27751 \| 33.83122 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 San Diego \| California \| United States \| -117.16472 \| 32.71571 Torrance \| California \| Uni...	249	NCT00857766	1COMPLETED	2010-03-01	2009-03-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	-0
[ 4 ]	64	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein (non-HDL) cholesterol levels with aripiprazole than with their current atypical antipsychotic tr...	null	Schizophrenia Schizoaffective Disorder Bipolar I Disorder Metabolic Syndrome		null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks intervention 2: Oanzapine, risperidone, or quetiapine administered orally as t...	intervention 1: Aripiprazole intervention 2: Oanzapine, risperidone, or quetiapine	14	Calgary \| Alberta \| Canada \| -114.08529 \| 51.05011 Pentincton \| British Columbia \| Canada \| N/A \| N/A Vancouver \| British Columbia \| Canada \| -123.11934 \| 49.24966 Hamilton \| Ontario \| Canada \| -79.84963 \| 43.25011 London \| Ontario \| Canada \| -81.23304 \| 42.98339 Markham \| Ontario \| Canada \| -79.2663 \| 43.86682 Mississ...	26	NCT00857818	6TERMINATED	2010-03-01	2009-04-01	Otsuka Pharmaceutical Development & Commercialization, Inc.	4INDUSTRY	false	false	false	null	0
[ 4 ]	260	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The primary objective of this study is to demonstrate the superiority of MCI-196 over placebo and non-inferiority with simvastatin in reducing serum low-density lipoprotein (LDL)-cholesterol in subjects with chronic kidney disease Stage V on dialysis. This study incorporates a Washout Period and two treatment periods -...	null	Chronic Kidney Disease	Chronic Kidney Disease Dialysis Dyslipidemia Bile acid sequestrant	null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 0, 2, 1, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20) intervention 2: Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdraw...	intervention 1: MCI-196 intervention 2: Placebo of Simvastatin intervention 3: Simvastatin intervention 4: Placebo of MCI-196	39	Brest \| N/A \| Belarus \| 23.71749 \| 52.10894 Grodno \| N/A \| Belarus \| 23.8942 \| 53.62865 Homyel \| N/A \| Belarus \| 30.9754 \| 52.4345 Minsk \| N/A \| Belarus \| 27.56653 \| 53.90019 Vitebsk \| N/A \| Belarus \| 30.2049 \| 55.1904 Gabrovo \| N/A \| Bulgaria \| 25.33417 \| 42.87472 Plovdiv \| N/A \| Bulgaria \| 24.75 \| 42.15 Sofia \| N/A \|...	259	NCT00858637	1COMPLETED	2010-03-01	2009-03-01	Mitsubishi Tanabe Pharma Corporation	4INDUSTRY	false	false	false	null	0
[ 0 ]	16	RANDOMIZED	CROSSOVER	0TREATMENT	1SINGLE	false	0ALL	true	This research is a prospective, randomized, cross-over study that is being done to compare the effect of morning only, evening only and twice daily insulin glargine (Lantus®) on hypoglycemia (blood glucose level \<70 mg/dL) as measured by continuous glucose monitoring (CGM) in patients with type 1 diabetes.	Over the course of the 6 week study, patients will take insulin glargine in each of 3 different times: only in the morning, only at night, and half in the morning, half at night. After 2 weeks taking the insulin in one regimen, patients will be switched to another regimen. Through the whole study, patients will be inje...	Type 1 Diabetes Hypoglycemia	hypoglycemia type 1 diabetes split dosing insulin glargine continuous glucose monitoring	null	3	arm 1: Morning only administration of insulin glargine arm 2: Evening only administration of insulin glargine arm 3: Split dose administration of insulin glargine, half dose in morning, half dose in evening	[ 1, 1, 1 ]	3	[ 0, 0, 0 ]	intervention 1: Evening only administration of insulin glargine, with normal saline injection administered in the morning. intervention 2: Morning only administration of insulin glargine, with normal saline injection administered at night. intervention 3: split dose of insulin glargine, half administered in the morning...	intervention 1: Evening only administration of insulin glargine intervention 2: Morning only administration of insulin glargine intervention 3: split dose insulin glargine	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	0	NCT00869414	6TERMINATED	2010-03-01	2009-07-01	Johns Hopkins University	7OTHER	false	false	false	null	0
[ 5 ]	271	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This study will evaluate the effect of omalizumab on markers of impairment in patients with inadequately controlled persistent allergic asthma on Step 4 or above therapy as defined in the 2007 National Heart, Lung, and Blood Institute (NHBLI) Guidelines	null	Persistent Allergic Asthma	Asthma; asthma management; asthma impairment ; Xolair ; omalizumab	null	2	arm 1: The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used. arm 2: Placebo was administered subcutaneously every 2 weeks or e...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple i...	intervention 1: Omalizumab intervention 2: Placebo	50	Jasper \| Alabama \| United States \| -87.27751 \| 33.83122 Anchorage \| Alaska \| United States \| -149.90028 \| 61.21806 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Encinitas \| California \| United States \| -117.29198 \| 33.03699 Fresno \| California \| United States \| -119.77237 \| 36.74773 Huntington Beach \| Ca...	271	NCT00870584	1COMPLETED	2010-03-01	2009-03-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 2 ]	64	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	false	This study will measure and compare changes in insulin production and sensitivity using the hyperglycemic clamp technique in obese patients with impaired glucose tolerance and hypertension treated with placebo, isosorbide mononitrate (ISMN) or hydrochlorothiazide (HCTZ).	null	Hypertension		null	4	arm 1: Placebo in Period 1 followed by HCTZ in Period 2 arm 2: HCTZ in Period 1, followed by placebo in Period 2 arm 3: Placebo in Period 1, followed by ISMN in Period 2 arm 4: ISMN in Period 1, followed by placebo in Period 2	[ 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period. intervention 2: Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period intervention 3: ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period intervention 4: Placebo to ISMN 0 mg ...	intervention 1: Hydrochlorothiazide (HCTZ) intervention 2: Comparator: Placebo to HCTZ intervention 3: Isosorbide mononitrate (ISMN) intervention 4: Comparator: Placebo to ISMN	0	null	128	NCT00871871	1COMPLETED	2010-03-01	2009-03-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0
[ 2 ]	28	RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	true	0ALL	true	This is a Phase 1 study to assess the pharmacokinetics (PK) of IK-1001 (sodium sulfide) in healthy volunteers as well as in subjects with varying degrees of impaired renal function. A total of 28 subjects will be enrolled into the study over a 6 month period. There will be 4 cohorts. The first cohort will consist of su...	This is a Phase 1 pharmacokinetic study to assess the pharmacokinetics of IK-1001 in healthy volunteers as well as subjects with varying degrees of impaired renal function following a single intravenous infusion. A total of 28 subjects will be enrolled into the study, including 6 normal subjects (Creatinine Clearance ...	Renal Impairment	Renal Impairment Renal Disease Sodium Sulfide	null	4	arm 1: Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours. arm 2: Healthy subjects received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours arm 3: Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours arm 4: Severe RI ...	[ 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours intervention 2: Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours intervention 3: Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours intervention 4: Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours	intervention 1: Sodium Sulfide intervention 2: Sodium Sulfide intervention 3: Sodium Sulfide intervention 4: Sodium Sulfide	1	Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997	28	NCT00879645	6TERMINATED	2010-03-01	2009-08-01	Mallinckrodt	4INDUSTRY	false	false	false	null	0
[ 5 ]	60	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purposes of this study are: 1. To understand whether the use of HIV therapy in persons with more advanced HIV disease results in greater side effects. 2. To determine whether these side effects can be related to greater activation of the immune system.	1. To compare the incidence and severity of self-reported symptoms in persons with CD4 counts \<100 cells/mm3 versus those with CD4 counts ≥ 100 cells/mm3 who are initiating antiretroviral therapy. 2. To determine the relationship between self-reported symptoms and levels of T cells, HIV RNA, activation marker cytokine...	HIV Infections	HIV immune reconstitution treatment naive	null	2	arm 1: All participants were treated but at baseline by design were divided based upon their CD4 count at baseline measurement. Group with CD4\<100 cells/cu mm arm 2: All participants were treated but at baseline by design were divided based upon their CD4 count at baseline measurement. Group with CD4\>/=100 cells/cu m...	[ 5, 5 ]	2	[ 0, 0 ]	intervention 1: Tenofovir/emtricitabine fixed dose combination once daily intervention 2: Lopinavir/ritonavir 400/100 mg twice daily	intervention 1: Truvada (tenofovir/emtricitabine) intervention 2: Kaletra (lopinavir/ritonavir)	1	Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711	60	NCT00885664	1COMPLETED	2010-03-01	2005-10-01	University of Cincinnati	7OTHER	false	false	false	null	0
[ 3 ]	200	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	true	0ALL	true	The aim of the study is to see if lozenges containing a low dose of interferon-alpha can prevent and/or reduce the severity of colds and flu. Starting about 1 month before the expected start of the winter colds and flu season in Perth, Australia, healthy volunteers will allow a lozenge containing interferon, or a lozen...	null	Upper Respiratory Tract Infections	Prophylaxis Treatment Symptoms Winter Colds and Flu	null	2	arm 1: 150 international units of interferon-alpha arm 2: placebo lozenges	[ 0, 2 ]	2	[ 0, 10 ]	intervention 1: a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks intervention 2: placebo lozenges for oral dissolution taken once daily for 16 weeks	intervention 1: interferon-alpha intervention 2: placebo	1	Nedlands \| Western Australia \| Australia \| 115.8073 \| -31.98184	198	NCT00895947	1COMPLETED	2010-03-01	2009-04-01	Ainos, Inc. (f/k/a Amarillo Biosciences Inc.	4INDUSTRY	false	false	false	null	0
[ 5 ]	30	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment period, and to evaluate safety of escitalopram.	The study will be performed in Russia, as an open-label, uncontrolled, one arm trial. The patients will receive escitalopram for 12 weeks. Start and maintenance dosages as well as dose titration will be left to the investigators' decision (5 to 20 mg/day), in accordance with the national Summary of Products Characteris...	Social Anxiety Disorder	Social Anxiety Disorder SAD Antidepressant Anxiolytic	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Flexible-dosed (5 to 20 mg Oral Tablets Daily)	intervention 1: Escitalopram	1	Moscow \| N/A \| Russia \| 37.61556 \| 55.75222	30	NCT00902226	1COMPLETED	2010-03-01	2009-03-01	H. Lundbeck A/S	4INDUSTRY	false	false	false	null	0
[ 5 ]	30	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to evaluate the effect of escitalopram after 8 weeks of treatment in patients with Generalized Anxiety Disorder (GAD), to evaluate proportion of patients who respond to escitalopram during the treatment period, and to evaluate safety of escitalopram.	The study will be performed in Russia, as an open-label, uncontrolled, one arm trial. The patients will receive escitalopram for 8 weeks. Start and maintenance dosages as well as dose titration will be left to the investigators' decision (5 to 20 mg/day), in accordance with the national Summary of Products Characterist...	Generalized Anxiety Disorder	Generalized Anxiety Disorder GAD Antidepressant Anxiolytic	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Flexible-dosed (5 to 20 mg Oral Tablets Daily)	intervention 1: Escitalopram	1	Moscow \| N/A \| Russia \| 37.61556 \| 55.75222	30	NCT00902564	1COMPLETED	2010-03-01	2009-03-01	H. Lundbeck A/S	4INDUSTRY	false	false	false	null	0
[ 2 ]	47	RANDOMIZED	CROSSOVER	9OTHER	0NONE	true	2MALE	false	The purpose of this study is to perform a relative bioavailability study between two formulations of sildenafil citrate.	Bio-equivalence between two formulations of sildenafil citrate	Erectile Dysfunction	Sildenafil Bio-equivalence	null	3	arm 1: None arm 2: None arm 3: None	[ 0, 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: sildenafil citrate 100 mg CT, single dose without water intervention 2: sildenafil citrate 100 mg CT, single dose with water intervention 3: sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose	intervention 1: sildenafil citrate 100 mg CT intervention 2: sildenafil citrate 100 mg CT intervention 3: Viagra®	1	Bragança Paulista \| São Paulo \| Brazil \| -46.54418 \| -22.9527	188	NCT00904748	1COMPLETED	2010-03-01	2010-01-01	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	239	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.	This was a multicenter, double-blind, parallel group, active and placebo-controlled, three arm study of a single oral dose of NXN-188 for the treatment of acute migraine headache with aura. After study eligibility was confirmed, subjects were randomized to NXN-188 600 mg, sumatriptan 100 mg, or placebo in a 1:1:1 rati...	Migraine With Aura	Migraine aura	null	3	arm 1: NXN-188, 600 mg, PRN arm 2: Sumatriptan, 100 mg, PRN arm 3: matching, PRN	[ 0, 1, 2 ]	3	[ 0, 0, 0 ]	intervention 1: NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules intervention 2: administered as 3 placebo hard gelatin capsules intervention 3: administered in a hard gelatin capsule with 2 capsules of placebo	intervention 1: NXN-188 intervention 2: placebo intervention 3: sumatriptan succinate	16	Newport Beach \| California \| United States \| -117.92895 \| 33.61891 Oceanside \| California \| United States \| -117.37948 \| 33.19587 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Santa Monica \| California \| United States \| -118.49138 \| 34.01949 St. Petersburg \| Florida \| United States \| -82.67927 \| 27...	185	NCT00920686	1COMPLETED	2010-03-01	2009-06-01	NeurAxon Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	1	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Background: * Pioglitazone is a drug that belongs to the class of antidiabetic agents called thiazolidinediones. It is approved for treatment of type 2 diabetes mellitus. * Research suggests that the thiazolidinediones may have anticancer activity that can reduce cancer risk or cause tumors to shrink. Objectives: -T...	Background: Lung cancer is the leading cause of cancer deaths in the United States (US). Chemoprevention is an active area of investigation for reducing the burden of this disease. However, the choice of chemopreventive targets requires sufficient human data to justify extensive clinical interventions. Peroxisome pro...	Non-Small-Cell Lung Cancer	NSCLC Stage Ia-IIb Resectable NSCLC Non-Small Cell Lung Cancer NSCLC	null	1	arm 1: 45 mg tablet daily by mouth for six weeks	[ 0 ]	1	[ 0 ]	intervention 1: 45 mg tablet daily by mouth for six weeks	intervention 1: Pioglitazone	2	Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067 New York \| New York \| United States \| -74.00597 \| 40.71427	1	NCT00923949	6TERMINATED	2010-03-01	2008-08-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0
[ 3 ]	329	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks treatment with AZD3199 in moderate to severe COPD.	null	COPD	COPD Efficacy Safety Inhalation	null	5	arm 1: AZD3199 low dose arm 2: AZD3199 intermediate dose arm 3: AZD3199 high dose arm 4: Formoterol 2x4.5 microgram bid arm 5: Placebo	[ 0, 0, 0, 1, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Dry powder for inhalation, o.d., 4 weeks intervention 2: Dry powder for inhalation, b.i.d., 4 weeks intervention 3: Dry powder for inhalation, b.i.d., 4 weeks	intervention 1: AZD3199 intervention 2: formoterol intervention 3: Placebo	38	Blagoevgrad \| N/A \| Bulgaria \| 23.1 \| 42.01667 Pleven \| N/A \| Bulgaria \| 24.61667 \| 43.41667 Rousse \| N/A \| Bulgaria \| 25.9534 \| 43.84872 Sofia \| N/A \| Bulgaria \| 23.32415 \| 42.69751 Varna \| N/A \| Bulgaria \| 27.91667 \| 43.21667 Moncton \| New Brunswick \| Canada \| -64.7965 \| 46.09454 St. John's \| Newfoundland and Labrado...	329	NCT00929708	1COMPLETED	2010-03-01	2009-06-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 3 ]	10	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The objective of this study is to evaluate the efficacy of apremilast in patients with recalcitrant atopic or contact dermatitis.	Atopic Dermatitis (AD) is a chronic, inflammatory skin disease characterized by dry, red, and itchy patches that can become thickened and lichenified with time. Contact Dermatitis, or Allergic Contact Dermatitis (ACD), is an eczematous reaction in response to an environmental allergen. The etiology of Atopic Dermatiti...	Atopic Dermatitis Allergic Contact Dermatitis	eczema dermatitis TNF blockade PDE4 inhibitor T cell inhibitor	null	1	arm 1: Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).	[ 0 ]	1	[ 0 ]	intervention 1: Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).	intervention 1: Apremilast	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	12	NCT00931242	1COMPLETED	2010-03-01	2009-06-01	Tufts Medical Center	7OTHER	false	false	false	null	0
[ 3 ]	107	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this trial is to study the efficacy and safety of Visonac PDT in patients from 9 to 35 years old with Aktilite® CL512. Patients was randomized to Visonac or vehicle cream without occlusion and red light(dose: 37J/cm2)	Double blinded, prospective, randomized, stratified, placebo-controlled, multi-center study in patients with moderate to severe acne vulgaris. Patients with facial severity grades 3 to 4 on the Investigator's Global Assessment (IGA) scale will be included. Each patient will be classified according to age in the two age...	Acne Vulgaris	Acne Vulgaris Moderate to severe	null	2	arm 1: Active treatment, Light dose 37 J/cm2. arm 2: Placebo treatment, Light dose 37 J/cm2.	[ 0, 2 ]	3	[ 0, 0, 3 ]	intervention 1: Cream application followed by illumination with red light. intervention 2: Cream application followed by illumination with red light. intervention 3: Photodynamic Therapy - Light dose 37 J/cm2	intervention 1: Visonac PDT (MAL PDT) intervention 2: Vehicle cream (placebo) intervention 3: PDT	11	San Diego \| California \| United States \| -117.16472 \| 32.71571 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Naperville \| Illinois \| United States \| -88.14729 \| 41.78586 Fridley \| Minnesota \| United States \| -93.26328 \| 45.08608 Rochester \| New York \| United States \| -77.61556 \| 43.15478 Hershey \| Pennsylva...	107	NCT00933543	1COMPLETED	2010-03-01	2009-08-01	Photocure	4INDUSTRY	false	false	false	null	0
[ 5 ]	412	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The purpose of the study is to compare the combination of aliskiren, amlodipine and Hydrochlorothiazide (HCTZ) versus the combination of aliskiren and amlodipine as therapy in minority Stage 2 hypertensive patients.	null	Hypertension	Hypertension Aliskiren Amlodipine HCTZ Systolic blood pressure Diastolic blood pressure Stage II Combination	null	2	arm 1: At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25...	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Amlodipine capsule (5 mg) Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg) intervention 2: Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg) HCTZ capsule (12.5 mg, 25mg)	intervention 1: Aliskiren/Amlodipine intervention 2: Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)	5	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 South Miami \| Florida \| United States \| -80.29338 \| 25.7076 Mattapan \| Massachusetts \| United States \| -71.087 \| 42.27232 Manassas \| Virginia \| United States \| -77.47527 \| 38.75095 Seattle \| Washington \| United States \| -122.33207 \| 47.60621	411	NCT00942994	1COMPLETED	2010-03-01	2009-06-01	Novartis	4INDUSTRY	false	false	false	null	0
[ 5 ]	163	RANDOMIZED	PARALLEL	1PREVENTION	0NONE	false	0ALL	true	The study will assess the use of paliperidone palmitate compared with oral risperidone in delaying time to relapse in patients recently diagnosed with schizophrenia who are at high risk of relapse.	This is a Prospective, Randomized, Active-controlled, Rater-blinded Study to to assess the efficacy of paliperidone palmitate compared with oral risperidone in delaying time to relapse in patients recently diagnosed with schizophrenia who are at high risk of relapse. Recently diagnosed is defined as first diagnosis of ...	Schizophrenia	Schizophrenia Risperidone Risperdal Paliperidone Palmitate Invega Sustenna	null	2	arm 1: paliperidone palmitate 50 75 100 or 150 mg eq. monthly injection for 2 years arm 2: oral risperidone 2 4 6 or 8 mg tabs once daily for two years	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 50, 75, 100, or 150 mg eq. monthly injection for 2 years intervention 2: 2, 4, 6, or 8 mg tabs once daily for two years	intervention 1: paliperidone palmitate intervention 2: oral risperidone	72	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Garden Grove \| California \| United States \| -117.94145 \| 33.77391 San Diego \| California \| United States \| -117.16472 \| 32.71571 Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Kissimmee \| Florida \| United States \| -81.41667 \| 2...	162	NCT00946985	6TERMINATED	2010-03-01	2009-06-01	Ortho-McNeil Janssen Scientific Affairs, LLC	4INDUSTRY	false	false	false	null	0
[ 3 ]	12	RANDOMIZED	PARALLEL	6HEALTH_SERVICES_RESEARCH	2DOUBLE	true	0ALL	false	This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin release when GLP-1 is not allowed to be rapidly inactivated.	The purpose of the present proposal is to 1) examine the role of dipeptidyl peptidase (DPP-4) inhibition on insulin release during a hyperglycemic clamp while GLP-1 is being infused and, 2) further elucidate the role of the metabolite of GLP-1, that is GLP-1 9-36 amide (GLP-1m). During stable and very reproducible elev...	Glucose Homeostasis	Healthy volunteers GLP-1 Januvia Sitagliptin	null	2	arm 1: None arm 2: None	[ 2, 1 ]	2	[ 0, 0 ]	intervention 1: 1 tablet 100 mg once a day intervention 2: 1 tablet 100 mg once a day	intervention 1: Placebo intervention 2: Januvia	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	0	NCT00947011	6TERMINATED	2010-03-01	2009-03-01	Johns Hopkins University	7OTHER	false	false	false	null	0
[ 3 ]	195	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This is a a multi-center, randomized, double-blind, parallel group, and placebo controlled, two-arm study of a single oral dose of NXN-188 for the treatment of acute migraine headache without aura. Up to 120 migraineurs will be enrolled. Approximately 60 subjects having a headache history of migraine without aura will ...	After study eligibility was confirmed and all screening procedures completed, subjects were randomized at Visit 1 to receive either NXN-188 600 mg or placebo in a 1:1 ratio. Study drug and diaries were dispensed, and subjects were instructed regarding when to dose with study drug. Subjects were also trained regarding t...	Migraine Without Aura	migraine	null	2	arm 1: 3 x 200 mg capsules, PRN arm 2: 3 x 0 mg capsules, PRN	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 200 mg capsules, 600 mg, PRN intervention 2: 200 mg capsules with no active ingredient designed to match the NXN-188 capsules	intervention 1: NXN-188 intervention 2: Placebo	4	St. Petersburg \| Florida \| United States \| -82.67927 \| 27.77086 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Mount Vernon \| New York \| United States \| -73.83708 \| 40.9126 Salt Lake City \| Utah \| United States \| -111.89105 \| 40.76078	174	NCT00959751	1COMPLETED	2010-03-01	2009-07-01	NeurAxon Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	25	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	To study how the body absorbs, distributes, metabolises and eliminates Keppra XR in both children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.	null	Epilepsy	Levetiracetam Epilepsy Children Adults	null	2	arm 1: None arm 2: None	[ 0, 0 ]	1	[ 0 ]	intervention 1: Keppra XR 500 mg tablets and Keppra XR 750 mg tablets Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days	intervention 1: Keppra XR	6	Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Fairfield \| Connecticut \| United States \| -73.26373 \| 41.14121 Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067 Dallas \| Texas \| Unite...	25	NCT00961441	1COMPLETED	2010-03-01	2009-09-01	UCB BIOSCIENCES, Inc.	4INDUSTRY	false	false	false	null	0
[ 4 ]	403	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.	This is a Phase III, multi-center, investigator-blinded, two-arm, randomized, parallel group study, evaluating the safety and efficacy of a Malathion Gel, 0.5% formulation, manufactured by Taro. The objective is to show superiority of the novel product to an active control, Nix® Crème Rinse, manufactured by Insight Pha...	Pediculosis	Head Lice	null	2	arm 1: Malathion gel 0.5% 30 minute application arm 2: Nix Crème Rinse applied to scalp for 10 minutes	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present. intervention 2: Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.	intervention 1: Malathion gel 0.5% intervention 2: Permethrin 1% rinse (Nix Crème)	7	Hot Springs \| Arkansas \| United States \| -93.05518 \| 34.5037 Sacramento \| California \| United States \| -121.4944 \| 38.58157 Kissimmee \| Florida \| United States \| -81.41667 \| 28.30468 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Ormond Beach \| Florida \| United States \| -81.05589 \| 29.28581 Picayune \| Mississip...	403	NCT00963508	1COMPLETED	2010-03-01	2009-08-01	Sun Pharmaceutical Industries, Inc.	4INDUSTRY	false	false	false	null	0
[ 4 ]	13	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.	This eight-week study aims to assess the effectiveness and tolerability of escitalopram in improving symptoms of Major Depression in patients with Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) as measured by the HAM-D. In addition, the study will assess improvement in the quality of life in patients wi...	Major Depression Multiple Sclerosis Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis ALS Multiple Sclerosis MS Major Depression Depression Major Depressive Disorder antidepressants Escitalopram Lexapro	null	1	arm 1: All patients will receive escitalopram 20 mg daily.	[ 0 ]	1	[ 0 ]	intervention 1: After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medic...	intervention 1: escitalopram	1	Columbia \| South Carolina \| United States \| -81.03481 \| 34.00071	14	NCT00965497	1COMPLETED	2010-03-01	2009-07-01	University of South Carolina	7OTHER	false	false	false	null	0
[ 5 ]	51	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.	null	Glaucoma	Glaucoma IOP Travoprost	null	2	arm 1: Travoprost first, with tafluprost second. Each product dosed for six weeks. arm 2: Tafluprost first, with travoprost second. Each product dosed for six weeks.	[ 5, 5 ]	2	[ 0, 0 ]	intervention 1: One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration intervention 2: One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration	intervention 1: Travoprost 0.004% ophthalmic solution (TRAVATAN) intervention 2: Tafluprost 0.0015% ophthalmic solution	0	null	99	NCT00966940	1COMPLETED	2010-03-01	2009-09-01	Alcon Research	4INDUSTRY	false	false	false	null	0
[ 3 ]	3	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	false	The treatment of cervical cancer with chemotherapy and radiation will make women post menopausal (no estrogen from the ovaries), if a woman is not already in menopause. Estrogen plays a key role in maintaining bone health. Therefore, these women are at higher risk of getting osteoporosis (decrease minerals in the bone)...	OBJECTIVES * To determine the incidence of disseminated tumor cells (DTCs) in bone marrow and circulating tumor cells (CTCs) in the blood of women with cervical cancer at diagnosis and 3 to 9 months after chemotherapy and pelvic radiation with and without Zometa. * To determine the change in biochemical markers of bon...	Uterine Cervical Neoplasms	Uterine Cervical Cancer Cancer of Cervix Cervix Cancer	null	2	arm 1: Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. All interventions on this arm are standard of care. arm 2: Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about...	[ 4, 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: Zoledronic acid	1	St Louis \| Missouri \| United States \| -90.19789 \| 38.62727	3	NCT00966992	6TERMINATED	2010-03-01	2009-08-01	Washington University School of Medicine	7OTHER	false	false	false	null	0
[ 3, 4 ]	184	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This is a controlled trial of amantadine to improve level of function following severe traumatic brain injury. The purpose of this study is: 1. To determine whether amantadine hydrochloride, given in a dose of 200-400 mg, improves functional recovery from the vegetative and minimally conscious states 2. To determine ...	Severe traumatic brain injury may result in severe disorders of consciousness (DOC), including coma, the vegetative state (VS) and the minimally conscious state (MCS). The longer the duration of impaired consciousness, the worse the ultimate functional prognosis, with only about half of those individuals who remain unc...	Traumatic Brain Injury	Traumatic Brain Injury Rehabilitation Disorders of Consciousness Functional Outcome Amantadine Hydrochloride	null	2	arm 1: 100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4. arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) ser...	intervention 1: Amantadine Hydrochloride intervention 2: Placebo	11	Braintree \| Massachusetts \| United States \| -71.00215 \| 42.20384 Jackson \| Mississippi \| United States \| -90.18481 \| 32.29876 New York \| New York \| United States \| -74.00597 \| 40.71427 Schenectady \| New York \| United States \| -73.93957 \| 42.81424 Charlotte \| North Carolina \| United States \| -80.84313 \| 35.22709 Elkins ...	184	NCT00970944	1COMPLETED	2010-03-01	2003-02-01	JFK Medical Center	7OTHER	false	false	false	null	0
[ 5 ]	138	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	This clinical trial will evaluate the efficacy and safety of Clobex® (clobetasol propionate) Spray 0.05% and Vectical™ (calcitriol) Ointment 3 µg/g over a four week period of use in one of two different regimens: 1. Vectical™ Ointment treatment, twice daily on weekdays (Mon - Fri) and Clobex® Spray treatment twice dai...	null	Plaque Psoriasis		null	2	arm 1: Vectical™ Ointment weekdays \& Clobex® Spray weekends regimen arm 2: Clobex® Spray morning and Vectical™ Ointment evening regimen	[ 5, 5 ]	2	[ 0, 0 ]	intervention 1: Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days intervention 2: Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days	intervention 1: Vectical™ Ointment weekdays and Clobex® Spray weekends regimen intervention 2: Clobex® Spray morning and Vectical™ Ointment evening regimen	6	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Diego \| California \| United States \| -117.16472 \| 32.71571 Evansville \| Indiana \| United States \| -87.55585 \| 37.97476 Fridley \| Minnesota \| United States \| -93.26328 \| 45.08608 Dallas \| Texas \| United States \| -96.80667 \| 32.78306 Waterloo \| Ontario ...	138	NCT00988637	1COMPLETED	2010-03-01	2009-10-01	Galderma R&D	4INDUSTRY	false	false	false	null	0
[ 2, 3 ]	4	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	2MALE	true	The primary objectives of this study are to evaluate the safety and best dose of a regimen including bevacizumab and erlotinib in combination with docetaxel and prednisone. In addition, the investigators wish to evaluate how well these drugs might work against this disease. Bevacizumab and erlotinib are novel drugs tha...	In this Phase I/Phase II study, the primary objectives are to establish the maximum tolerated dose of docetaxel, erlotinib, bevacizumab, and prednisone in patients with metastatic hormone refractory prostate cancer and to determine the efficacy of this regimen for treatment of metastatic HRPC. In the phase I portion of...	Prostate Cancer		null	1	arm 1: Bevacizumab, Erlotinib, Docetaxel, Prednisone (dose escalation) Phase I: * Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid * Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab...	[ 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Phase I: * Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle * Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle * Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle intervention 2: 15mg/kg of Bevacizumab every 3 weeks intervention 3: 200 mg of Erlotinib PO daily days 2-16 intervention 4: 5 mg ...	intervention 1: Docetaxel intervention 2: Bevacizumab intervention 3: Erlotinib intervention 4: Prednisone	1	New York \| New York \| United States \| -74.00597 \| 40.71427	0	NCT00996502	6TERMINATED	2010-03-01	2006-07-01	Columbia University	7OTHER	false	false	false	null	0
[ 4 ]	54	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	0ALL	null	This study compared the effects of a single dose of indacaterol with that of a single dose of tiotropium on inspiratory capacity.	null	Chronic Obstructive Pulmonary Disease	COPD indacaterol tiotropium	null	3	arm 1: Patients received indacaterol 150 μg once. After a 5-9 days washout period, patients received tiotropium 18 μg once. After a second 5-9 days washout period, patients received placebo (matching indacaterol) once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agoni...	[ 0, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device. intervention 2: Tiotropium was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device. intervention 3: Placebo (matching indacaterol) was supplied i...	intervention 1: Indacaterol 150 μg intervention 2: Tiotropium 18 μg intervention 3: Placebo	11	Bergamo \| N/A \| Italy \| 9.66721 \| 45.69601 Brescia \| N/A \| Italy \| 10.21472 \| 45.53558 Cava de' Tirreni \| N/A \| Italy \| 14.70773 \| 40.69954 Genova \| N/A \| Italy \| 11.87211 \| 45.21604 Milan \| N/A \| Italy \| 12.59836 \| 42.78235 Orbassano \| N/A \| Italy \| 7.53813 \| 45.00547 Pavia \| N/A \| Italy \| 9.15917 \| 45.19205 Reggio Em...	157	NCT00999908	1COMPLETED	2010-03-01	2009-10-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	-0
[ 3 ]	21	RANDOMIZED	CROSSOVER	0TREATMENT	3TRIPLE	false	0ALL	false	Respiratory diseases including Asthma are high prevalent among preschool children. Specific treatment, nowadays, include steroid inhalers and anti leukotrienes. It is known that the amount of the drug reaching small airways and lungs is bigger how much smaller the particles liberated by inhalers. Beclometasone is being...	26 - 30 patients, between 3 -6 years old, mild asthmatics, with positive adenosine challenge test, will received in a randomized, double blind, cross over assignment Beclometasone dipropionate (100µg twice a day) or placebo, through an inhaler (autohaler) device, attached to a spacer device, during four consecutive wee...	Asthma Bronchial Hyperresponsiveness	asthma preschool children bronchial hyperresponsiveness beclometasone dipropionate - HFA Qvar Adenosine Challenge test	null	2	arm 1: Controlled or partially controlled multiple trigger wheezing children received 4 weeks of placebo, preceded and succeeded by AMP challenge test, arm 2: Patients will receive 4 weeks of inhale QVAR (HFA beclomethasone) 100µg through a spacer device, twice a day	[ 2, 1 ]	2	[ 0, 0 ]	intervention 1: 100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test intervention 2: inhalation twice a day for one month, preceded and followed by adenosine challenge test	intervention 1: Beclomethasone dipropionate HFA intervention 2: placebo	1	Haifa \| N/A \| Israel \| 34.99928 \| 32.81303	21	NCT01006655	1COMPLETED	2010-03-01	2009-03-01	Rambam Health Care Campus	7OTHER	false	false	false	null	0
[ 4 ]	258	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to evaluate the efficacy and safety of fentanyl in opioid-naive participants with post-herpetic neuralgia, complex regional pain syndrome or post-operative pain syndrome who cannot obtain a sufficient analgesic effect by the treatment of non-opioid analgesics (drug used to control pain).	This is a multi-center (conducted in more than one center), double-blind (neither the participant nor the physician knows the assigned study drug), randomized (participants assigned study drug by chance), withdrawal study in opioid-naive participants with post-herpetic neuralgia (intense, typically intermittent pain al...	Postherpetic Neuralgia Complex Regional Pain Syndromes (CRPS) Postoperative Pain	Postherpetic Neuralgia Complex Regional Pain Syndromes (CRPS) Postoperative Pain Fentanyl Patch, transdermal Opioid analgesics	null	3	arm 1: One-day adhesive transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2...	[ 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day. intervention 2: Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper a...	intervention 1: Fentanyl intervention 2: Placebo	79	Aichi \| N/A \| Japan \| 130.62158 \| 32.51879 Amagasaki \| N/A \| Japan \| 135.41667 \| 34.71667 Asahikawa \| N/A \| Japan \| 142.36489 \| 43.77063 Bunkyō City \| N/A \| Japan \| 139.4217 \| 35.5331 Chigasaki \| N/A \| Japan \| 139.40434 \| 35.33638 Chūō \| N/A \| Japan \| 139.77544 \| 35.67004 Ebetsu \| N/A \| Japan \| 141.55056 \| 43.10806 Fuj...	421	NCT01008553	1COMPLETED	2010-03-01	2008-12-01	Janssen Pharmaceutical K.K.	4INDUSTRY	false	false	false	null	0
[ 3 ]	35	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	null	This study assessed the efficacy, safety, tolerability, and pharmacokinetics of two different formulations of indacaterol, one administered via the Concept1 device and one administered via the Simoon device. The study aimed to determine whether the novel formulation (Simoon) had a similar profile to that of the establi...	This study was double-blind with regards to the Concept1, where placebo for the lactose-blended indacaterol was available. However, with regards to the Simoon, neither the subject nor the investigator was blinded due to lack of a placebo to the PulmoSphere formulation. Hence, the overall designation of the study was pa...	Asthma	asthma QAB149 indacaterol pulmonary function	null	4	arm 1: In treatment period 1, patients received indacaterol 150 μg via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received placebo to indacaterol via the Concept1 DPI; in treatment period 3, patients received indacaterol 60 μg via the Simoon DPI; and in treatment period 4, patients received ...	[ 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler. intervention 2: Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler. intervention 3: Indacaterol 120 μg was provided in powder filled capsules with the Simoon d...	intervention 1: Indacaterol 150 μg via the Concept1 dry-powder inhaler intervention 2: Indacaterol 60 μg via the Simoon dry-powder inhaler intervention 3: Indacaterol 120 μg via the Simoon dry-powder inhaler intervention 4: Placebo to indacaterol via the Concept1 dry-powder inhaler	4	Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Groningen \| N/A \| Netherlands \| 6.56667 \| 53.21917 Belfast \| N/A \| United Kingdom \| -5.92541 \| 54.59682 Manchester \| N/A \| United Kingdom \| -2.23743 \| 53.48095	135	NCT01012739	1COMPLETED	2010-03-01	2009-10-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 5 ]	2	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	null	The purpose of this study is to assess if a single dose of Diclofenac potassium (0.5 mg/kg) is more or as effective as a single dose of Acetaminophen (10 mg/kg) in the reduction of fever during 2 hours, in the treatment of febrile children with acute upper respiratory infections. This is a comparative double blind, do...	null	Fever	Antipyretics fever diclofenac acetaminophen children acute upper respiratory tract infections	null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Diclofenac potassium intervention 2: Acetaminophen	intervention 1: Diclofenac potassium intervention 2: Acetaminophen	2	Caracas \| N/A \| Venezuela \| -66.87919 \| 10.48801 Estado Carabobo \| N/A \| Venezuela \| N/A \| N/A	0	NCT01019980	6TERMINATED	2010-03-01	2010-03-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 4 ]	357	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	This study is to evaluate the safety and efficacy of loteprednol etabonate \[LE\] and tobramycin ophthalmic suspension versus tobramycin and dexamethasone ophthalmic suspension in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis (BKC).	null	Conjunctivitis Keratitis Blepharitis	Blepharokeratoconjunctivitis	null	2	arm 1: Loteprednol etabonate and tobramycin ophthalmic suspension arm 2: Tobramycin and dexamethasone ophthalmic suspension	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days. intervention 2: Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.	intervention 1: Loteprednol and tobramycin intervention 2: Tobramycin and dexamethasone	1	Singapore \| N/A \| Singapore \| 103.85007 \| 1.28967	354	NCT01028027	1COMPLETED	2010-03-01	2009-10-01	Bausch & Lomb Incorporated	4INDUSTRY	false	false	false	null	0
[ 4 ]	618	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	2MALE	false	Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-5 versus placebo for the treatment of subjects with erectile dysfunction (ED).	null	Erectile Dysfunction		null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 2, 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: Tablets via oral administration before an attempt at sexual intercourse. intervention 2: Tablets via oral administration before an attempt at sexual intercourse.	intervention 1: Udenafil intervention 2: Placebo	36	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Homewood \| Alabama \| United States \| -86.80082 \| 33.47177 Mesa \| Arizona \| United States \| -111.82264 \| 33.42227 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Laguna Hills \| California \| Unit...	616	NCT01037244	1COMPLETED	2010-03-01	2009-09-01	Warner Chilcott	4INDUSTRY	false	false	false	null	-0
[ 3 ]	378	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.	null	Common Cold	common cold	null	2	arm 1: None arm 2: None	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: bid 7 days intervention 2: bid 7 days	intervention 1: guaifenesin (Mucinex) intervention 2: placebo	1	Bellevue \| Nebraska \| United States \| -95.89084 \| 41.13667	377	NCT01046136	1COMPLETED	2010-03-01	2009-12-01	Reckitt Benckiser Inc.	4INDUSTRY	false	false	false	null	0
[ 5 ]	123	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Although approved for minor strains, sprains and contusions, FLECTOR Patch has not been studied extensively in the setting of acute back strain. This study is being conducted as an initial step in demonstrating the benefit of FLECTOR Patch specifically for back strain. In particular, this study is expected to provide i...	null	Acute Back Strain	FLECTORÂ® Patch acute back strain	null	1	arm 1: One patch applied every 12 hours	[ 0 ]	1	[ 0 ]	intervention 1: One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.	intervention 1: FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%	0	null	123	NCT01054820	1COMPLETED	2010-03-01	2010-01-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 2 ]	50	RANDOMIZED	CROSSOVER	7BASIC_SCIENCE	0NONE	true	2MALE	false	The major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of two Rotigotine patches of two different formulations	null	Healthy Volunteers	Rotigotine Neupro® Transdermal Patch	null	2	arm 1: Rotigotine transdermal patch 4.5 mg/10 cm\^2, test drug product PR2.2.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm\^2, reference drug product PR2.1.1 separated by a washout phase of at least 5 days arm 2: Rotigotine transdermal patch 4.5 mg/10 cm\^2, reference drug product PR2.1.1 followed by Rotigoti...	[ 0, 0 ]	1	[ 0 ]	intervention 1: Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours	intervention 1: Rotigotine transdermal patch	1	Mönchengladbach \| North Rhine-Westphalia \| Germany \| 6.44172 \| 51.18539	98	NCT01059903	1COMPLETED	2010-03-01	2010-01-01	UCB Pharma	4INDUSTRY	false	false	false	null	0
[ 3 ]	25	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	true	1FEMALE	false	The purpose of this study was to assess the safety and efficacy of a new metallic cannula to inject hyaluronic acid for dermal augmentation in the nasolabial folds compared to standard needle.	This was a monocentric, prospective, randomized, phase II and double-blind study. At the baseline visits, one investigator rated the severity of nasolabial folds on both left and right sides according to the mentioned scale, and a standard set of six photographs of the face (frontal, left side and right side for both ...	Wrinkles	metallic cannula Hyaluronic acid	null	2	arm 1: Nasolabial Fold with metallic cannula and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle. Hyaluronic acid injected with the new tool arm 2: Nasolabial Fold with standard needle and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle.	[ 0, 1 ]	2	[ 3, 0 ]	intervention 1: The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices: * In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard ne...	intervention 1: hyaluronic acid with metallic cannula or standard needle. intervention 2: Hyaluronic acid injected with the new tool.	2	Porto Alegre \| Rio Grande do Sul \| Brazil \| -51.23019 \| -30.03283 Porto Alegre \| N/A \| Brazil \| -51.23019 \| -30.03283	50	NCT01066026	1COMPLETED	2010-03-01	2009-07-01	Brazilan Center for Studies in Dermatology	7OTHER	false	false	false	null	0
[ 2 ]	27	RANDOMIZED	CROSSOVER	null	0NONE	true	0ALL	false	To demonstrate the bioequivalence of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet to that of 2.5-mg saxagliptin (Onglyza) and 500-mg metformin (Glucophage, marketed in Canada by Sanofi-Aventis) tablets coadministered to healthy participants in the fasted and fed states.	null	Type 2 Diabetes Mellitus		null	4	arm 1: Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fasted state arm 2: Single oral dose of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet administered in the fasted state arm 3: Single oral doses of saxagliptin, 2.5 mg, and metformi...	[ 5, 5, 5, 5 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week intervention 2: Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week intervention 3: Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week intervention 4: Tablet...	intervention 1: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state) intervention 2: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state) intervention 3: Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state) intervention 4: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)	1	Austin \| Texas \| United States \| -97.74306 \| 30.26715	105	NCT01068717	1COMPLETED	2010-03-01	2010-03-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 2 ]	24	RANDOMIZED	CROSSOVER	null	0NONE	true	0ALL	false	To demonstrate bioequivalence of a 2.5 mg saxagliptin/850 mg metformin fixed dose combination (FDC) tablet relative to the 2.5 mg saxagliptin tablet and 850 mg metformin (Glucophage Marketed by Merck-Serono) tablet co-administered to healthy subjects in the fasted and fed condition.	null	Type 2 Diabetes Mellitus		null	4	arm 1: A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fasted condition. arm 2: A single oral dose of 2.5-mg saxagliptin/850-mg metformin fixed dose combination (FDC) administered in the fasted condition. arm 3: A single oral dose of 2.5-m...	[ 5, 5, 5, 5 ]	3	[ 0, 0, 0 ]	intervention 1: Tablets, Oral, 2.5 mg, once daily, single dose intervention 2: Tablets, Oral, 850 mg, once daily, single dose intervention 3: Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose	intervention 1: saxagliptin intervention 2: metformin intervention 3: saxagliptin + metformin (FDC tablet)	1	Austin \| Texas \| United States \| -97.74306 \| 30.26715	94	NCT01068743	1COMPLETED	2010-03-01	2010-02-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 5 ]	401	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	GlaxoSmithKline will be conducting this trial to compare analgesic efficacy of paracetamol 1000 mg vs 650 mg. The post-surgical dental pain model will be used to evaluate the analgesic efficacy of paracetamol. Each subject will be enrolled in the study for up to six weeks. The duration of the entire study will be appro...	null	Post-surgical Dental Pain	dental pain paracetamol Post-surgical dental pain	null	3	arm 1: Paracetamol 1000mg arm 2: Paracetamol 650 mg arm 3: Placebo	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Paracetamol 1000mg intervention 2: Paracetamol 650 mg intervention 3: Placebo	intervention 1: Paracetamol 1000 mg intervention 2: Paracetamol 650 mg intervention 3: Placebo	1	Salt Lake City \| Utah \| United States \| -111.89105 \| 40.76078	401	NCT01075243	1COMPLETED	2010-03-01	2009-11-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0
[ 5 ]	300	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	GlaxoSmithKline will be conducting this trial to compare analgesics efficacy of paracetamol 1000mg vs 500mg . The post-surgical dental pain model will be used to evaluate the analgesic efficacy of paracetamol. Each subject will be enrolled in the study for up to six weeks. The duration of the entire study will be appro...	null	Post-surgical Dental Pain	paracetamol dental pain Post-surgical dental pain	null	3	arm 1: Paracetamol 1000 mg arm 2: Paracetamol 500 mg arm 3: Placebo	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Paracetamol 1000 mg intervention 2: Paracetamol 500 mg intervention 3: Placebo	intervention 1: Paracetamol 1000 mg intervention 2: Paracetamol 500 mg intervention 3: Placebo	2	Austin \| Texas \| United States \| -97.74306 \| 30.26715 Salt Lake City \| Utah \| United States \| -111.89105 \| 40.76078	300	NCT01082081	1COMPLETED	2010-03-01	2009-10-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0
[ 5 ]	153	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	false	0ALL	false	The purposes of this study are to document the antiemetic efficacy of multimodal antiemetic protocol in patient after Total Knee Arthroplasty using regional anesthesia, midazolam \& propofol, hydration \& oxygen supplement, preemptive \& multimodal contemporary pain management and to determine whether Ramosetron prophy...	Immediate postoperative pain after Total Knee Arthroplasty(TKA) remains an unsolved problem, and a substantial proportion of patients experience moderate to severe postoperative pain. Patient controlled analgesia(PCA) using opioid is an effective and safe modality for postoperative pain relief after TKA and remains an ...	Osteoarthritis, Knee	postoperative nausea and vomiting	null	2	arm 1: ramosetron prophylaxis at the end of surgery with starting PCA and 1 day after surgery arm 2: no antiemetic prophylaxis	[ 0, 4 ]	1	[ 0 ]	intervention 1: ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days	intervention 1: Ramosetron	1	Seongnam-si \| Gyeonggi-do \| South Korea \| 127.13778 \| 37.43861	142	NCT01102491	1COMPLETED	2010-03-01	2009-09-01	Seoul National University Hospital	7OTHER	false	false	false	null	0
[ 2 ]	13	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This study will evaluate the safety and tolerability of single doses of MK-0941 based on assessment of clinical and laboratory adverse experiences	null	Type 2 Diabetes		null	4	arm 1: Period 1: Placebo - Period 2: 80 mg - Period 3: 100 mg - Period 4: Placebo - Period 5: 140 mg arm 2: Period 1: 60 mg - Period 2: 80 mg - Period 3: 100 mg - Period 4: 120 mg - Period 5: Placebo arm 3: Period 1: 60 mg - Period 2: Placebo - Period 3: 100 mg - Period 4: 120 mg - Period 5: 140 mg arm 4: Period 1: 60 ...	[ 0, 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period intervention 2: a single oral placebo will be administered in the designated period (Periods 1-5)	intervention 1: MK-0941 intervention 2: Comparator: Placebo	0	null	59	NCT01106287	1COMPLETED	2010-03-01	2009-10-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0
[ 5 ]	55	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The purpose of this study is to determine whether the combinational use of ammonium lactate lotion 12% (Lac-Hydrin) and halobetasol propionate ointment 0.05% (Ultravate) is safe and effective in the initial treatment and long-term maintenance of psoriasis. Patients will use both medications continuously for two weeks a...	This is a randomized, double-blind, placebo-controlled, clinical trial assessing the efficacy of Ultravate ointment in combination with Lac-Hydrin lotion in the treatment of plaque psoriasis. In the first phase, patients will be treated for two weeks with combination therapy using Ultravate ointment twice daily along w...	Plaque Psoriasis	plaque psoriasis lac-hydrin ammonium lactate Ultravate halobetasol propionate weekend only application topical therapy topical corticosteroid class I steroid	null	2	arm 1: Lac-Hydrin lotion twice daily everyday + Ultravate ointment twice daily on weekends only arm 2: Lac-Hydrin lotion twice daily everyday + placebo ointment twice daily on weekends only	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Steroid on weekends only group intervention 2: Placebo on weekends only group	intervention 1: Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%) intervention 2: Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment	1	New York \| New York \| United States \| -74.00597 \| 40.71427	41	NCT01111123	1COMPLETED	2010-03-01	2009-01-01	Icahn School of Medicine at Mount Sinai	7OTHER	false	false	false	null	0
[ 0 ]	11	RANDOMIZED	CROSSOVER	4SUPPORTIVE_CARE	3TRIPLE	false	0ALL	false	The purpose of this prospective study is to compare pain levels and pain medication dose requirements in patients with topical negative pressure (TNP) dressings removed in a standard manner (i.v. or p.o. pain meds) compared to dressings removed with lidocaine analgesia, via injection retrograde up the suction tube into...	null	Pain	Wound Vacuum Assisted Dressings Lidocaine Dressing change Pain management palliative care	null	2	arm 1: None arm 2: None	[ 2, 1 ]	2	[ 0, 0 ]	intervention 1: Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge. intervention 2: Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.	intervention 1: Lidocaine intervention 2: Placebo-Saline	1	Salt Lake City \| Utah \| United States \| -111.89105 \| 40.76078	21	NCT01126359	1COMPLETED	2010-03-01	2008-08-01	University of Utah	7OTHER	false	false	false	null	0
[ 0 ]	107	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	true	0ALL	false	Introduction Numerous drugs and combinations of drugs are used for procedural sedation and analgesia (PSA) in Emergency Departments, including propofol, ketamine, benzodiazepines, narcotics, barbiturates, and others, but propofol has gained popularity despite its potential to cause cardiac and respiratory depression. ...	Introduction Numerous drugs and combinations of drugs are used for procedural sedation and analgesia (PSA) in Emergency Departments, including propofol, ketamine, benzodiazepines, narcotics, barbiturates, and others, but propofol has gained popularity despite its potential to cause cardiac and respiratory depression. ...	Procedural Sedation and Analgesia		null	2	arm 1: Participants received 0.5-1.5 micrograms/kg Fentanyl, followed 0.5 mg/kg Ketamine infusion, followed by propofol to maintain sedation. arm 2: Participants received 0.5-1.5 micrograms/kg Fentanyl, followed by placebo infusion, followed by propofol to maintain sedation.	[ 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Ketamine was given as a 0.5mg / Kg bolus. intervention 2: Placebo given as an bolus to control group. intervention 3: Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo intervention 4: Propofol given to both arms to maintain sedation throughout procedure.	intervention 1: Ketamine intervention 2: Placebo intervention 3: Fentanyl intervention 4: Propofol	1	Columbia \| Missouri \| United States \| -92.33407 \| 38.95171	0	NCT01126957	6TERMINATED	2010-03-01	2007-05-01	University of Missouri-Columbia	7OTHER	false	false	false	null	0
[ 5 ]	83	RANDOMIZED	CROSSOVER	1PREVENTION	2DOUBLE	true	0ALL	false	This study will use an oral in-situ caries model to study remineralization of enamel due to the action of different combinations of fluoride salts delivered from dentifrices.	null	Dental Caries	Enamel remineralization Fluoride caries	null	4	arm 1: Fluoride toothpaste containing sodium fluoride (NaF) arm 2: Fluoride toothpaste containing stannous fluoride (SnF) and NaF. arm 3: Fluoride toothpaste containing sodium monofluorophosphate (NaMFP) and NaF. arm 4: Low fluoride toothpaste containing NaF	[ 0, 0, 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF. intervention 2: Fluoride toothpaste containing stannous fluoride (1100 ppmF) intervention 3: Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)	intervention 1: NaF intervention 2: SnF intervention 3: NaMFP	1	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838	318	NCT01128946	1COMPLETED	2010-03-01	2009-11-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0
[ 0 ]	50	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	null	The purpose of this study is to specifically investigate the efficacy of an alternative pharmacologic cervical ripening agent, misoprostol, versus the standard oxytocin, as an adjunct to Foley balloon for induction of the unfavorable cervix.	The design of this study is a randomized, controlled study with two arms. Both groups will undergo placement of a Foley catheter, through the external and internal os of the cervix, according to standard practice. In group A, receiving intravenous infusion of oxytocin, will serve as the control group as it is standard ...	Induction of Labor	Cervical Ripening Rate of Cesearean Section	null	2	arm 1: Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute. arm 2: Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement	[ 1, 0 ]	2	[ 0, 0 ]	intervention 1: Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute. intervention 2: Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement	intervention 1: Oxytocin intervention 2: Misoprostol	1	Canton \| Ohio \| United States \| -81.37845 \| 40.79895	50	NCT01139801	1COMPLETED	2010-03-01	2009-09-01	Aultman Health Foundation	7OTHER	false	false	false	null	0
[ 4 ]	610	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	false	0ALL	null	The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.	null	Prevention Venous Thromboembolism	Anticoagulants Venous thromboembolism Thromboembolism Thrombosis enoxaparin sodium Embolism Deep vein thrombosis DU-176b edoxaban factor Xa total hip arthroplasty	null	2	arm 1: DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery. arm 2: enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: edoxaban intervention 2: enoxaparin sodium	2	Osaka \| N/A \| Japan \| 135.50107 \| 34.69379 Tokyo \| N/A \| Japan \| 139.69171 \| 35.6895	604	NCT01181167	1COMPLETED	2010-03-01	2009-05-01	Daiichi Sankyo Co., Ltd.	4INDUSTRY	false	false	false	null	0
[ 0 ]	102	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	Intravenous phenobarbital in combination with a symptom-guided standardized lorazepam-based alcohol withdrawal protocol will be associated with decreased need for ICU admission, continuous lorazepam infusion and will not be associated with increased adverse events.	null	Alcohol Withdrawal		null	2	arm 1: 10 mg/kg IV phenobarbital in 100 ml saline arm 2: 100 ml saline	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: 10 mg/kg IV phenobarbital in 100 ml saline intervention 2: 100 m l saline	intervention 1: 10 mg/kg IV phenobarbital in 100 ml saline intervention 2: placebo	1	Oakland \| California \| United States \| -122.2708 \| 37.80437	102	NCT01184417	1COMPLETED	2010-03-01	2009-01-01	Jonathan Rosenson	7OTHER	false	false	false	null	0
[ 5 ]	22	RANDOMIZED	PARALLEL	9OTHER	0NONE	true	0ALL	false	The purpose of this study is to find out if presurgical antiseptic preparations affect how well surgical drapes adhere to skin.	Adhesive incise drapes are often used to provide a physical sterile barrier between the surrounding skin and the open wound at the beginning of a surgery. This study sought to determine the effect of presurgical skin antiseptic preparation on the adhesion of various incise drapes to the skin.	Healthy		null	2	arm 1: Applied ChloraPrep on the application site per manufacturer's instruction arm 2: Apply DuraPrep to the application site per manufacturer's instruction	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule intervention 2: The application sites (subjects' backs) will be prepped with DuraP...	intervention 1: ChloraPrep intervention 2: DuraPrep	1	Broomall \| Pennsylvania \| United States \| -75.35658 \| 39.9815	22	NCT01290978	1COMPLETED	2010-03-01	2010-02-01	Solventum US LLC	4INDUSTRY	false	false	false	null	0
[ 5 ]	133	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (ER) in symptomatic participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) who wer...	This is an open-label (all people know the identity of the intervention), multi-centric (conducted in more than one center) and non-comparative study of paliperidone ER in participants with schizophrenia who have a previous history of bad adherence to the antipsychotic treatment because of insufficient efficacy and sid...	Schizophrenia	Schizophrenia Paliperidone	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.	intervention 1: Paliperidone ER	0	null	132	NCT01362439	1COMPLETED	2010-03-01	2009-01-01	Janssen-Cilag S.p.A.	4INDUSTRY	false	false	false	null	0
[ 5 ]	31	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to compare serum concentrations of inflammatory cytokines, interleukin 6 (IL-6), High-sensitivity C-reactive protein (hs-CRP), adiponectin, and tumour necrosis factor alpha (TNFα), before and after three months treatment with metformin in obese adolescents with insulin resistance (IR).	The increased prevalence of obesity in pediatric patients is a public health problem particularly because of the difficulties involved with changing lifestyles. Current studies of obese children and adolescents show increased insulin resistance (IR) and chronic inflammatory states. These conditions increase the risk of...	Obesity	Metformin Obesity Insulin resistance Interleukin six Adiponectin High sensitivity C reactive protein. Tumour Necrosis Factor alpha	null	2	arm 1: Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months. arm 2: Tablet of 500 mg oral placebo every 12 hours for 3 months.	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months. intervention 2: Tablet of 500 mg oral placebo every 12 hours for 3 months.	intervention 1: Metformin intervention 2: Placebo	2	León \| Guanajuato \| Mexico \| -101.67374 \| 21.12908 Mexico City \| Mexico City \| Mexico \| -99.12766 \| 19.42847	31	NCT01410604	1COMPLETED	2010-03-01	2007-01-01	Hospital Regional de Alta Especialidad del Bajio	7OTHER	false	false	false	null	0
[ 5 ]	201	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	1FEMALE	false	The purpose of this study is to evaluate the efficacy and safety of Ethinyl estradiol and Norgestimate (EE/NGM) compared to Ethinyl estradiol and Desogestrel (EE/DSG), for treatment of female participants with mild to moderate acne vulgaris (pimples).	This is a single-blind (physician does not know the name of the assigned drug) and randomized (study drug assigned by chance) study to compare the effectiveness and safety of EE/NGM and EE/DSG in female participants using oral contraceptive and have mild to moderate acne vulgaris. Tablets of EE/NGM and EE/DSG will be a...	Acne Vulgaris	Acne Vulgaris Ethinyl estradiol Norgestimate Desogestrel Tricilest Oilezz	null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each. interven...	intervention 1: Ethinyl estradiol/Norgestimate (EE/NGM) intervention 2: Ethinyl estradiol/Desogestrel (EE/DSG)	3	Bangkok \| N/A \| Thailand \| 100.50144 \| 13.75398 Bangkok \| N/A \| Thailand \| 100.50144 \| 13.75398 Chiang Mai \| N/A \| Thailand \| 98.98468 \| 18.79038	201	NCT01466673	1COMPLETED	2010-03-01	2008-12-01	Janssen-Cilag Ltd.,Thailand	4INDUSTRY	false	false	false	null	0
[ 2 ]	52	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	true	0ALL	false	To investigate the effect of BIA 9-1067 in steady-state conditions on the levodopa pharmacokinetics	Single centre, randomized, double-blind, gender-balanced, placebo-controlled study in 4 groups of healthy subjects	Parkinson Disease	Parkinson Disease BIA 9-1067	null	4	arm 1: 5 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28 arm 2: Placebo once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28. arm 3: 15 mg BI...	[ 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: None intervention 2: None intervention 3: None intervention 4: None	intervention 1: BIA 9-1067 intervention 2: Placebo intervention 3: levodopa/carbidopa intervention 4: levodopa/benserazide	1	Mount Royal \| Quebec \| Canada \| -73.64918 \| 45.51675	52	NCT01533116	1COMPLETED	2010-03-01	2009-03-01	Bial - Portela C S.A.	4INDUSTRY	false	false	false	null	0
[ 2 ]	59	RANDOMIZED	PARALLEL	7BASIC_SCIENCE	2DOUBLE	true	1FEMALE	false	The purpose of this study is to assess the safety and side effects of multiple doses of LY2541546 in postmenopausal women when given subcutaneously (injection just under the skin) and intravenously (directly into a vein). The study will also test how long it takes the study drug to get into the body, how long it takes ...	null	Healthy	Postmenopausal females Volunteers	null	6	arm 1: 180 milligram (mg) LY2541546 administered subcutaneous (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind. arm 2: 270 mg LY2541546 administered (SC) once every 2 weeks (Q2W) for 8 weeks. arm 3: 270 mg LY2541546 administered (SC) once every 4 weeks (Q4W) for ...	[ 0, 0, 0, 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Administered SC intervention 2: Administered IV intervention 3: Administered SC intervention 4: Administered IV	intervention 1: LY2541546 - SC intervention 2: LY2541546 - IV intervention 3: Placebo - SC intervention 4: Placebo - IV	5	Daytona Beach \| Florida \| United States \| -81.02283 \| 29.21081 Honolulu \| Hawaii \| United States \| -157.85833 \| 21.30694 Evansville \| Indiana \| United States \| -87.55585 \| 37.97476 Austin \| Texas \| United States \| -97.74306 \| 30.26715 Dallas \| Texas \| United States \| -96.80667 \| 32.78306	59	NCT01742091	1COMPLETED	2010-03-01	2009-09-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0
[ 3, 4 ]	66	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	false	This study will compare a fast-absorbing paracetamol plus caffeine formula with placebo and an over-the-counter dose of paracetamol and ibuprofen to treat episodic tension headache.	null	Headache, Tension-Type	caffeine paracetamol tension headache	null	4	arm 1: Placebo arm 2: paracetamol marketed forumulation arm 3: ibuprofen marketed formulation arm 4: experimental paracetamol + caffeine formulation	[ 2, 1, 1, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Placebo intervention 2: experimental paracetamol + caffeine formulation intervention 3: ibuprofen marketed formulation intervention 4: Paracetamol marketed formulation	intervention 1: Placebo intervention 2: Experimental paracetamol + caffeine formulation intervention 3: ibuprofen marketed formulation intervention 4: Paracetamol marketed formulation	7	Pembroke Pines \| Florida \| United States \| -80.22394 \| 26.00315 Springfield \| Massachusetts \| United States \| -72.58981 \| 42.10148 Wellesley Hills \| Massachusetts \| United States \| -71.27867 \| 42.30843 Lake Success \| New York \| United States \| -73.71763 \| 40.77066 Mount Vernon \| New York \| United States \| -73.83708 \| 4...	187	NCT01755702	6TERMINATED	2010-03-01	2009-07-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0
[ 2 ]	24	RANDOMIZED	CROSSOVER	null	2DOUBLE	true	0ALL	false	The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy Japanese participants. The study has four treatment periods. Participants will receive a single dose of LY2624803 or placebo in each treatment period.	null	Sleep Initiation and Maintenance Disorders		null	5	arm 1: Single dose of 0.1 mg LY2624803 administered orally in up to 2 of 4 treatment periods arm 2: Single dose of 1.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods arm 3: Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods arm 4: Single dose of 6.0 mg LY2624803 ad...	[ 0, 0, 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Administered orally as reconstituted solution intervention 2: Administered orally as a capsule intervention 3: Administered orally as solution intervention 4: Administered orally as a capsule	intervention 1: LY2624803 - Solution intervention 2: LY2624803 - Capsule intervention 3: Placebo - Solution intervention 4: Placebo - Capsule	1	Sagamihara \| N/A \| Japan \| 139.24167 \| 35.56707	91	NCT01784614	1COMPLETED	2010-03-01	2009-09-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0
[ 3, 4 ]	60	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Alzheimer's disease (AD), the most common dementing disorder of later life, is a major cause of disability and death in the elderly. Although a number of theoretical causes exist, the etiology of AD is still unknown. Consequently, the focus of treatments has been palliative, designed to ameliorate AD symptoms. Recent e...	The study is conducted in a sample of 35 elderly (50-90 years old) outpatients who meet study inclusion criteria for depression (DEP) (DSM-IV criteria for major depression, dysthymic disorder, or depression NOS) and mild cognitive impairment (MCI; e.g. operationally defined as between "normal" and "dementia"), i.e., De...	Mild Cognitive Impairment Major Depressive Disorder Alzheimer's Disease	Memory Decline Depression Elderly Antidepressants Treatment memantine	null	1	arm 1: concurrent es-citalopram plus memantine were administered for 48 weeks.	[ 0 ]	2	[ 0, 0 ]	intervention 1: es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2. intervention 2: After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.	intervention 1: es-citalopram intervention 2: Memantine	1	New York \| New York \| United States \| -74.00597 \| 40.71427	35	NCT01876823	1COMPLETED	2010-03-01	2006-04-01	New York State Psychiatric Institute	7OTHER	false	false	false	null	0
[ 2 ]	48	RANDOMIZED	CROSSOVER	7BASIC_SCIENCE	0NONE	true	0ALL	false	The purpose of this study is to assess the oral bioavailability of Apixaban solution formulation (Treatment B, 10 mg as 25 mL x 0.4 mg/mL) relative to Apixaban tablets (Treatment A, 10 mg as 2 x 5 mg tablets) in healthy subjects.	null	Healthy Volunteers		null	2	arm 1: Apixaban Film coated Tablet Single dose 10 mg orally arm 2: Apixaban Solution Single dose 10 mg orally	[ 0, 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: Apixaban	1	Neptune City \| New Jersey \| United States \| -74.02792 \| 40.20011	27	NCT02034565	1COMPLETED	2010-03-01	2010-02-01	Bristol-Myers Squibb	4INDUSTRY	false	false	false	null	0

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.